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0939-4753/ª 2014 Elsevier B.V. All rights reseAbstract Mounting evidence supports the hypothesis that functional foods containing physio-
logically-active components may be healthful. Longitudinal cohort studies have shown that some
food classes and dietary patterns are beneﬁcial in primary prevention, and this has led to the
identiﬁcation of putative functional foods. This ﬁeld, however, is at its very beginning, and addi-
tional research is necessary to substantiate the potential health beneﬁt of foods for which the
dietehealth relationships are not yet scientiﬁcally validated. It appears essential, however, that
before health claims are made for particular foods, in vivo randomized, double-blind, placebo-
controlled trials of clinical end-points are necessary to establish clinical efﬁcacy. Since there is
need for research work aimed at devising personalized diet based on genetic make-up, it seems
more than reasonable the latter be modeled, at present, on the Mediterranean diet, given the
large body of evidence of its healthful effects.
The Mediterranean diet is a nutritional model whose origins go back to the traditional diet
adopted in European countries bordering the Mediterranean sea, namely central and southern
Italy, Greece and Spain; these populations have a lower incidence of cardiovascular diseases than
the North American ones, whose diet is characterized by high intake of animal fat. The meetingl Foods and Cardiometabolic Diseases” held in Naples on 1 June 2013.
Farinaro).
rved.
Functional foods 12731 The authors of this section are Salvain Naples and this document both aim to focus on the changes in time in these two different
models of dietary habits and their fall out on public health.
ª 2014 Elsevier B.V. All rights reserved.Figure 1 (A) Consequences of myosine mutations in the masticatory
muscles of early hominins that ultimately provoked, on one hand, the
need to look for more tender food, and on the other hand, activation ofAn overview of nutritional genomics and of the
geneeenvironment interaction1
The dawning of the brain versus brawn struggle
To understand the emergence of nutritional genomics, one
must inevitably start with the history of human nutrition.
This is traditionally traced back to about 2.5 million years
ago, when soon after the appearance of Lucy, the nutri-
tional phenotypes of the human species are thought to
have appeared, and much later, in the Neolithic, when
nutritional phenotypes of human populations began to
emerge. A major event that was not only to condition
human diets but also to shape human destiny, and that
eventually transformed hunteregatherers into digital na-
tives, was the emergence of a frame-shift mutation that
“switched-off” the myosin heavy chain (MYH16) gene that
was expressed in the masticatory muscles of monkeys.
Using the coding sequence of the myosin rod domains as a
molecular clock, Stedman et al. [1] dated, the loss of this
protein isoform, which caused a reduction in the size of
these muscles, to about 2.4 million years ago. This may be
considered the ﬁrst example of nutritional genomics.
Indeed, it is a striking case of a mutation inducing a drastic
change in nutrition and thus in lifestyle.
As shown in Fig. 1A, the loss of the MYH16 protein
isoform and the consequent appearance of less powerful
masticatory muscles together with other random muta-
tions in early hominins that led to the upright position,
prompted these populations to search for more tender
food, which in turn resulted in migration to the savannah/
woodland interface to gain access to the soft bone marrow
of the carcasses of carnivore preys [1]. The new food
provoked epi-mutations, which, probably with germinal
mutations, promoted a hierarchy of organs (Fig. 1B). In fact,
encephalization, namely, brain enlargement, resulted in
improved structural, cognitive and problem-solving ability
that are features typical of humans. Synergistically, evo-
lution, based also on dietary changes, produced a reduc-
tion in gut length thereby releasing energy for brain
development. Thus, a virtuous circle was set in motion
between brain development and nutrition, thereby
generating not only the brain versus brawn struggle but also
the brain versus gut struggle (Fig. 1C) [2]. This scenario
vividly evokes the challenging nature versus nurture
dilemma raised by Sir Francis Galton in 1857 of which
more below.brain expansion genes (brain versus brawn). (B) Interaction between
nutritional handicap and migration that would provoke the hierarchy
of organs in the human body during evolution. (C) The virtuous circle
that allowed greater brain development because of better nutrition and
a less developed gut. Source: Rotilio G. Roma: Carocci, 2012.tore F., Daniele A., Buono P.
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predictive medicine
To take a leap forward inman’s progress, the ﬁnding that all
living beings store their genetic material in their DNA pro-
vided the basis for the concept of risk. Being the probability
that an event will or will not happen, risk also indicates a
predisposition in terms of developing a disease. Ultimately,
it indicates a susceptibility to a disease when a gene variant
(or a series of gene variants) are present in a genome. Jonsen
and colleagues labeled subjects with a susceptibility to a
disease as “unpatients” [3], a term that aptly describes their
condition of being in a kind of limbo between health and
disease. This applies also to subjectswith avariant genotype
that prevents them from metabolizing a given nutrient,
which thus becomes toxic. In fact, such individuals are
“healthy” until they encounter the offending food.
Diet exerts a strong effect on such types of diseases that
are known as “single-gene autosomal recessive disorders”,
examples of which are phenylketonuria, galactosemia, and
fructose intolerance [4e6]. These conditions canbemanaged
by personalized nutrition strategies. Moreover, thanks to
new genetic laboratory tools, they can be identiﬁed in
newborn screening programs. Early detection and dietary or
supplement-driven treatment are crucial, for example, in
patients with phenylketonuria or other monogenic diseases,
and also in patients with multigenic dietary diseases (e.g.,
celiac disease), inwhich patients are advised to avoid a given
foodor to adhere to a speciﬁcdiet for theirwell-being [7e12].
More than 6000 human monogenic disorders have
been identiﬁed, including more than 100 protein-based
metabolic disorders. Some are rare and complex dietary
diseases, namely, fatty acid oxidation disorder, organic acid
metabolism disorders, urea cycle defects and glycogen
storage disease. Patients may reduce their intake of the
dietary substrates or metabolites that accumulate in such
diseases, and nutrigenomics will improve their prevention
and treatment by identifying speciﬁc mutations or haplo-
type combinations that modulate the dietary response in
affected subjects [13]. In multifactorial diseases like car-
diovascular diseases, obesity, type 2 diabetes mellitus,
cancer etc., nutrigenomic studies revealed that most of
them are amenable to dietary intervention that may
modulate their onset and progression [14]. This scenario
has contributed to the concept and practice of the mo-
lecular diagnosis of diseases, and to DNA tests that are
predictive, or even diagnostic of a given condition.
Nutritional therapy is based on nutritional science and
aimsatpromoting thehealth, performanceandwellbeingofa
person. This therapeutic approach uses a wide range of tools
to identify and assess nutritional problems and understand
how theymay contribute to health concerns [15]. Nutritional
therapy also addresses nutritional balance and aims at
maintaining health. This approach enhances the health and
wellbeing of patients with chronic conditions [16].
According to genomics, each subject is a unique entity and
consequently requires a personalized nutrition and lifestyle
plan rather than a “one size ﬁts all” approach. In fact, nutri-
tional and lifestyle approaches to healthcare improve thehealthof all themain tissues andorgansof the body (skeletal,
nervous, respiratory, cardiovascular, digestive, excretory,
endocrine, immune, and intertegumentary tissue) as well as
the brain. Typical priorities in nutritional therapies are to
obtainoptimumenergy levels, a healthy blood sugar balance,
emotional and psychological wellbeing, optimum gastroin-
testinal health and tolerance to a broad range of food groups.
Future advances in pre-emptive medicine based on
genetics, molecular diagnostics, and tailored interventions
will improve the prevention of various metabolic diseases.
Molecular diagnostics can identify subjects who are more
likely to respond positively to personalized nutrition.
Prediction is a crucial factor in medicine because it allows
one to prevent or even to cure a disease, whereas a
biomarker of a disease represents a target that can be
manipulated. A biomarker can also contribute to scientiﬁc
knowledge in terms of a better understanding of a disease,
and the way it starts and develops, and ﬁnally it can serve
as a therapeutic target [17e19]. Thus, the biomarker of
today is the theranostic of tomorrow e theranostics being
the development of diagnostic tests directly linked to the
application of speciﬁc therapies [20].
Nutrigenetics, nutrigenomics and personalized nutrition
Nutrigenetics and nutrigenomics: the potential role of
omics in targeted nutritional intervention
The concept that nutrients can interact and affect the
molecular mechanisms governing an individual’s physi-
ology generated two new disciplines: nutrigenetics and
nutrigenomics [21]. Following initial confusion about the
demarcations of the two disciplines and their terminology,
there is now general consensus as to the speciﬁcity and
meaning of each of them.
Nutrigenetics aims at identifying the genetic suscepti-
bility to the effect of nutrients based on the architecture of
the genome of each individual or group of individuals that
have the same DNA sequence at speciﬁc loci or in speciﬁc
gene(s), or even in a single (or a few) nucleotide poly-
morphisms. Although still in its infancy, the discipline is
already starting to provide personalized dietary advice to
people based on their genetic make-up. Nutrigenetics ex-
amines the impact of genetic variants on tolerance and
sometimes on nutritional requirements under physiolog-
ical and pathological conditions.
Nutrigenomics studies the effects of food and food con-
stituents on gene expression. This means it investigates
molecular interactions between nutrients and factors that
affect genome expression. The overall aims of nutrigenetics
and nutrigenomics are to provide better nutritional advice to
the public-at-large, to genetic subgroups, and to single in-
dividualswith the ultimate aimof personalizing nutrition for
a population with a presumably similar genetic background
and then homing down to the level of single individuals. The
two disciplines also aim at optimizing health, and at pre-
venting and treating diseases, thereby transforming the
practice of nutrition and dietetics into an evidence-based
science. In other words, nutrigenetics and nutrigenomics
may transform empiricism into scientiﬁc knowledge.
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explored how the interaction between genotype and envi-
ronmental exposure, including nutrition, affects an individual
[22]. Thus far,most nutritional interventions have been either
generic or tailored to population level rather than to the in-
dividual. For example, overweight subjects are, in general,
advised to consume fewer calories, and lactose-intolerant
subjects are advised to avoid or limit their milk intake,
whereas subjects carrying the TT allele in the methylente-
trahydrofolate (MTHFR) gene are advised to increase their
daily folate intake from 200 mg to 400e600 mg to maintain
theirhomocysteine serumconcentrationunder risk level [23].
Figure 2 shows the interactions between nutrition and
genetic factors, in other words, it shows the interaction
between nutrigenetics and nutrigenomics that leads to
variations in gene expression and ultimately to phenotype.
Epigenetics and nutrition
All complementary modiﬁcations that impact on gene
expression and function without modifying the genetic
code, are deﬁned “epigenetic”. Examples are histone
modiﬁcation and microRNAs, but the major epigenetic
process is, classically, DNA methylation. This is a common
more stable epigenetic marker transmitted through DNA
replication and cell division. DNA methylation induces
transcriptional silencing and can affect gene regulation in
response to the environment includingnutrition. Increasing
evidence indicates that early life environmental factors,
including nutrition, inﬂuence the future risk of developing a
given disease. For example, a diet rich in fat increases the
glucose level in fetal blood, whereas a protein-restricted
diet reduces the risk of type2 diabetes. The epigenetic
regulation of the methylation status of speciﬁc CpG loci in
the peroxisome proliferator-activated receptor gamma,
coactivator 1 alpha (PGC1A) gene in endocrine pancreas b-
cells was found to be associated with insulin secretion in
patients with type 2 diabetes, whereas methylation in the
fat mass and obesity-associated (FTO) gene in blood lym-
phocytes was associated with this disease. Furthermore, aFigure 2 Outline of the nutritionegene interactions that result in the
ﬁnal phenotype. The latter depends on the gene expression speciﬁc to
each individual, which in turn depends on both gene variability and
nutrition, which in turn exert epigenetic effects that may modulate
gene interactions. Modiﬁed from: Dauncey M. J., Proc Nutr Soc. 2012;
71:581e91.genotypeeepigenotype interaction was described between
haplotype-speciﬁc methylation in FTO-associated type 2
diabetes and the obesity locus. Thus, epigenetic markers
may be induced before the onset of symptoms and will be
predictive of disease risk [see Ref. [24]].
Role of genetic testing in personalized nutrition
Omics technology aims at increasing knowledge about the
effects exerted by food on human metabolism, and at
shedding light on the genetic determinants of these effects
in individuals thereby opening the way to personalized
nutrition. Personalized nutrition is designed to provide
appropriate care to agiven individual at the appropriate time
thereby reducing the risk of disease and health care costs, as
well as optimizing health and improving disease outcome.
Currently, personalized nutrition based on genetic infor-
mation is considered premature. However, there has been a
growth in the market for genetic analyses aimed at the
general public. Most of the kits combine nutritional advice
with nutritional supplements and biomarker assessment
tests. Recently, the U.S. Government Accountability Ofﬁce
judged these tests misleading for consumers because they
make predictions that are not adequately supported by sci-
entiﬁc evidence. The European Council Working Party on
Human Genetics also discussed the question of selling ge-
netic tests to the public without reaching a decision.
Interestingly, also “systems biology” has been exploited
in the ﬁeld of personalized nutrition. In fact, mathematical
modeling can be applied to dietary information and to an
individual’s metabolic proﬁle to obtain a “nutrigenomic
score”, which may lead to system biomarkers that can be
used to shed light on an individual’s nutritional tendencies
(Fig. 3). A fast emerging concept is that of themicrobiota, the
study of which could impinge on nutritional therapy [25].
To conclude this section, the interactions among geno-
type, dietary exposure and disease risk are a matter of
intense research. The scientiﬁc evidence that a direct
interaction between speciﬁc genotype and dietaryFigure 3 The attempt to devise a “nutrigenomic score” for disease risk
and to develop systems “biomarkers” based on multiple inter-related
measurements. Source: Hesketh J, Eur J Clin Nutr. 2013; 67:430e5.
Reproduced with permission from Nature Publishing Group.
Figure 4 Nutrition as a driving force in human well being. Note how
the genetic aspects of the human genome and the human microbioma,
by interacting with the exposome, in which nutrition plays a central
role, inﬂuence each individual’s gene expression thereby leading to his/
her phenotype.
2 The authors of this section are Stranges S., Farinaro E, Salvatore V,
Della Valle E.
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diseases is, at present, fragmentary and does not yet sup-
port the widespread application of personalized nutrition.
Nutritional interventions and calorie restriction
A less sophisticated aspect of nutrition is calorie restric-
tion. Notwithstanding its lack of sophistication, calorie
restriction is not only a major determinant of longevity but
it can also reduce the incidence of neuro- and cardio-
degenerative diseases, and even cancer [26]. This has been
demonstrated in species ranging from yeast to mammals.
In fact, calorie restriction reduced cardiovascular and
cancer mortality by 50% in rhesus monkeys [27]. It also
reduced age-associated brain atrophy in non-human pri-
mates. In man, recent experiments conducted in members
of the Calorie Restriction Association demonstrated that
this restriction dramatically modiﬁes the transcriptional
proﬁle of skeletal muscle [28].
We now have preliminary data that the expression of
several longevity-associated enzymes is several fold higher
in human ﬁbroblast cell lines incubated with sera from
calorie-restricted individuals than in cells from individuals
on a westernized diet. Moreover, we found a highly sig-
niﬁcant differential stress resistance to hydrogen peroxide
in the presence of calorie-restricted sera [29].
Nature and nurture: the exposome
The exposomemayhelp to solve the challenging nature versus
nurture dilemma in which nature, i.e., “genomics”, or the
innate quality of man, represents genetic features, whereas
nurture refers to all the environmental factors that interact
with genetic features. The latter interaction is crucial in un-
derstanding how human beings are and/or appear. The
exposomeisdeﬁnedas “everyexposure towhichan individual
is subjected from conception to death” or to a certain period
during which the observation is made (Fig. 4). In essence, it is
an environmental complement to each individual’s genome in
assessments of phenotype. And it is themeasure of the effects
of life-long environmental exposure on health. Exposome
studies have received funding from the European Commis-
sion, and the exposome concept is well recognized by the U.S.
National Institutes of Health. However, the major dilemma is
how to handle the daunting amount of data that theoretically
would need to be processed to evaluate a person’s lifelong
environmental exposure. The domains that should be evalu-
ated to produce an exposome score come under three head-
ings: general external factors, internal factors, and speciﬁc
external factors. One possible approach to this problem is
to evaluate exposure at key stages of life, for instance, infancy,
puberty, adolescence, and mid-life. These evaluations can
be combined to produce an exposome score; unfortunately,
this is beyond our reach at present. Figure 4 shows
howmodern concepts can reconcile “nature” with “nurture”.
In summary, the environment with its noxae, and an in-
dividual’s lifestyle, namely, nutrition, physical activity etc.,
affect the individual’s genotype, which, together with the
effects evaluated by pharmacogenomics and nutrigenomics,determines an individual’s phenotype, thus opening the
door to personalized medicine and personalized nutrition.
Lastly, nutritional genomics holds great promise for disease
identiﬁcation and prediction as well as for disease preven-
tion and treatment. For the present, one may apply the
simple equation: Eat less (calorie restriction) þ Eat better
(nutrigenomics)Z Hic manebimus optime.Acknowledgments
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Introduction
Use of dietary supplements has increasedmarkedly in recent
years, across several countries, because of the perception
Functional foods 1277that antioxidant vitamins and minerals may reduce the risk
of cardiovascular disease (CVD), cancer and other chronic
diseases [30]. However, there is inconclusive trial evidence
for a role of dietary supplements in chronic disease pre-
vention, at least among healthy individuals in the general
population. Moreover, concern has been raised about
possible adverse health effects for some of these supple-
ments, especially when they are used at high doses [31]. For
example, ﬁndings from randomized, controlled clinical trials
showed increased all-cause mortality with high-dose b-
carotene and vitamin E supplements, two antioxidant vita-
mins that were widely believed to be safe [32,33].
More speciﬁcally, selenium (Se) has been one of the
most extensively investigated micronutrients in chronic
disease prevention over the last two decades [34,35]. In
fact, Se is a key component of a number of selenoproteins
involved in essential enzymatic functions such as redox
homeostasis, thyroid hormone metabolism, immunity and
reproduction [36]. Because of the potential of these sele-
noproteins to protect against oxidative stress, signiﬁcant
expectations were raised for the prevention of several
chronic diseases including cancer, cardiovascular disease
(CVD), and type 2 diabetes [37], conditions commonly
associated with oxidative stress. However, recent ﬁndings
from observational studies and randomized clinical trials
have raised concern that high Se exposure may lead to
adverse cardio-metabolic effects, at least in well-nourished
populations [31].
Selenium and type 2 diabetes
Evidence from in vivo and in vitro studies suggests that Se
could enhance insulin sensitivity by mediating insulin-like
actions [38]. However, results from human studies on Se
and diabetes are conﬂicting. Recent ﬁndings from obser-
vational studies and randomized clinical trials from the US,
a Se-replete population, indicate that high Se status or Se
supplementation may be associated with an increased risk
of type 2 diabetes [39e41]. Speciﬁcally, in a post-hoc
analysis of the Nutritional Prevention of Cancer (NPC) trial,
in the eastern US, we found that supplementation with Se
(200 mg/day as high-Se yeast), compared to placebo,
increased the risk of type 2 diabetes [40], particularly
among participants with high baseline plasma Se (hazard
ratio of 2.70 in the highest tertile of plasma Se, i.e.
>121.6 ng/ml). Moreover, results from the large Selenium
and Vitamin E Cancer Prevention Trial (SELECT) in 35,533
North American men aged  50 y [41], showed a small,
though non-signiﬁcant, increase in the number of cases of
adult-onset diabetes in subjects supplemented with Se
alone (200 mg/day as selenomethionine). However, after a
further 33 months of follow-up in the SELECT trial, the risk
of diabetes further diminished: RR 1.04; 99%CI 0.91 to 1.18
[42]. Furthermore, a recent pooled longitudinal analysis
from two US cohorts (i.e. Health Professionals Follow-up
Study and Nurses’ Health Study) showed inverse associa-
tions between toenail selenium and incident type-2 dia-
betes; diabetes risk reduced as quintile of toenail selenium
increased [43].In European populations, where Se status is generally
lower than in the US, the evidence linking Se to glucose
metabolism is conﬂicting. For example, in an early analysis
of the EVA (Epidemiology of Vascular Ageing) study in
France, plasma Se concentrations were positively, though
non-signiﬁcantly, associated with baseline glucose levels
in women and with prevalent diabetes in men [44].
However, a later report from the same study showed that
high plasma Se (1.19e1.97 mmol/L) was associated with a
marginally signiﬁcant reduced risk of hyperglycaemia
(impaired fasting glucose or diabetes) in men over the 9-
year follow-up [45]. Conversely, in a prospective study
on a large sample of women from Northern Italy, an
increased risk of type-2 diabetes was associated with
higher dietary selenium intake; however it has to be
admitted that dietary assessments of selenium intake are
unreliable so not much weight can be attached to this
result [46].
With regard to trial evidence, in the French SU.VI.MAX
study, no effect of combined supplementation with anti-
oxidants including Se (100 mg/day as high-Se yeast), was
observed on fasting plasma glucose after 7.5 y of follow-up
despite a positive association between glucose and Se con-
centrations at baseline in the whole population [47].
Recently, in the PRECISE Trial (PREvention of Cancer by
Intervention with Selenium) among 501 elderly volunteers
treated for 6 months with 100, 200 or 300 mg selenium/d as
high-selenium yeast or placebo yeast, we found no effect of
selenium supplementation on plasma adiponectin, as a
surrogate marker of type-2 diabetes risk [48]. However,
limitations of this trial were the short duration (6 months)
and the limited age range (60e74 y) of the participants.
The explanation for these discrepant results is still un-
clear. Further research is needed to identify the optimal
range of Se intake and status in order to minimize po-
tential adverse effects on glucose metabolism while opti-
mizing type 2 diabetes prevention [49].
Selenium and blood lipids
A few studies from unrelated populations suggest that
high Se exposure may be associated with adverse effects
on lipid metabolism. Speciﬁcally, in the SU.VI.MAX trial,
plasma concentrations of Se were positively associated
with total cholesterol at baseline, while participants
receiving long-term supplementation with Se (100 mg/day)
and other nutrients had higher serum triglyceride con-
centrations than those on placebo [50]. Furthermore,
compared to those on placebo, women who were supple-
mented had higher total cholesterol levels while menwere
more likely to be using lipid-lowering medication. More-
over, a cross-sectional analysis of serum Se and lipid levels
in the NHANES III showed that high serum Se concentra-
tions were associated with high total, LDL- and HDL-
cholesterol, triglycerides, apo B, and apo A1 levels [51].
These ﬁndings were further corroborated by a recent
analysis from the NHANES 2003e2004 showing positive
associations between serum Se concentrations and blood
lipids in a representative sample of the US population [52].
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analysis from the 2000e2001 UK National Diet and
Nutrition Survey (NDNS) indicated that high-normal Se
status was associated with increased total and non-HDL
cholesterol, but not with increased HDL, in a nationally
representative sample of British adults [53]. In contrast to
the US, a signiﬁcant proportion of British adults are
considered to have a sub-optimal intake of dietary Se.
However, recent prospective ﬁndings from both the Young
Finns Study and the Olivetti Heart study do not support
the causality of the link between high selenium status and
adverse blood lipid proﬁles [54,55]. Finally, in the UK-
PRECISE trial the effect of a six-month supplementation
with 100, 200 or 300 mg selenium/day as high-selenium
yeast as compared to placebo were examined among 501
elderly volunteers with a mean plasma selenium concen-
tration at baseline of 88.8 ng/g (equivalent to 91.2 mg/L). In
this trial, supplementation at 100 and 200 mg selenium/
day lowered total serum cholesterol and non-HDL
cholesterol; the 300 mg/day dose had no signiﬁcant effect
on total or non-HDL cholesterol, but raised HDL-
cholesterol signiﬁcantly. In addition, the totaleHDL
cholesterol ratio decreased progressively with increasing
selenium dose [56].
Selenium and cardiovascular disease
A number of observational studies have examined the
association between Se status and risk of coronary heart
disease (CHD) across different populations [57]. Although
some of the early studies suggest possible inverse associ-
ations, especially in populations with relatively low Se
intakes, more recent observational evidence is suggestive
of a possible U-shaped association between Se status and
CHD risk, at least in well-nourished populations such as
that of the US [34]. However, results from randomized
trials of Se supplementation do not support a role for Se in
cardiovascular prevention [35]. Speciﬁcally, in post-hoc
analyses from the NPC trial [58], we found that Se sup-
plementation (200 mg/d) was not signiﬁcantly associated
with any of the cardiovascular disease (CVD) endpoints
after 7.6 years of follow-up [all CVD: hazard ratio
(HR) Z 1.03, 95% conﬁdence interval (CI): 0.78, 1.37;
myocardial infarction: HR Z 0.94, 95% CI: 0.61, 1.44;
stroke: HR Z 1.02, 95% CI: 0.63, 1.65; all CVD mortality:
HRZ 1.22, 95% CI: 0.76, 1.95]. Few other randomized trials
that examined the effect of Se in combination with other
vitamins or minerals on CVD end points have also yielded
null ﬁndings [57].
Potential mechanisms for adverse cardio-metabolic
effects of high selenium exposure
Evidence on potential mechanisms that may explain the
detrimental effect of high Se exposure on cardio-metabolic
health is sparse; therefore any such discussion is highly
speculative. However, Se is known to be a trace mineral
with a narrow therapeutic window and considerable inter-
individual variability in terms of metabolic sensitivity andselenoprotein polymorphisms [36]. In animal models, the
Se species (selenite and selenite), despite owning some
insulin-like properties, have been shown to impair insulin
responsiveness and induce a catabolic response in rat
muscle with glycogen depletion and increased rates of
glycolysis, and to reduce insulin release from pancreatic
islets in mice [49]. Moreover, it has been shown that high-
Se diets may stimulate the release of glucagon, promoting
hyperglycaemia, or may induce over-expression of gluta-
thione peroxidase (GPx) 1 and other antioxidant seleno-
proteins resulting in the development of insulin resistance
and obesity [49]. In general, the toxic effects of Se which
might explain an etiologic role in diabetes are the capacity
of Se compounds to induce oxidative stress [49], a mech-
anism that is likely to play a key role in the etiology of this
disease.Public health perspective
Potential adverse effect of dietary supplements such as Se
on cardio-metabolic health warrants further consideration
for several reasons. Firstly, in the UK and many other
Western countries, use of Se enriched foods, fertilizers, and
supplements has increased markedly in recent years
[36,37] because of the perception that Se can potentially
reduce the risk of cancer and other chronic diseases.
Hence, from a public health perspective, it is essential to
make sure that a higher Se status, which may result from
the increasing use of these additional sources of Se, does
not exacerbate the existing health, economic and social
burdens associated with diabetes, and other cardio-
metabolic disorders. Secondly, because of the current in-
terest in Se for chronic disease prevention, it is important
to understand the full range of effects of high Se exposure
on cardio-metabolic endpoints, including diabetes, lipids,
and CHD. Thirdly, dietary intakes of Se vary considerably
between countries and regions largely due to the vari-
ability of the Se content of plant foods (and hence of ani-
mal forage) from one part of the world to another [36,37]
and so may disease risk. Current recommendations for
dietary Se intake (55e75 mg/day) are based on optimizing
the activity of plasma GPx, which requires a plasma Se
concentration of 92 mg/L [59]. In the US, the mean serum
Se concentration among participants in the NHANES
2003e2004 was 137 mg/L, and most participants (99%) had
serum Se above 95 mg/L [52]. It is therefore likely that the
average NHANES participant would have had repleted
selenoprotein status, including that of selenoprotein P, the
carrier of Se in the plasma [59]. Health beneﬁts of addi-
tional Se intake in such a population are therefore ques-
tionable and toxic effects, such as an increase in diabetes
risk or adverse metabolic proﬁles, are possible. In Europe,
Se status is generally lower than in the US with a large
variability in dietary Se intakes by country, ranging from
levels considered to be marginally adequate or adequate
(Western and Central Europe: 30e90 mg/day) to low or
deﬁcient (Eastern European countries: 7e30 mg/day)
[36,37].
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Recent ﬁndings from observational studies and a few
randomized clinical trials have suggested potential
adverse cardio-metabolic effects associated with high
doses of micronutrient supplements, such as selenium.
However, this evidence has substantial limitations. Firstly,
most of these studies were conducted in North American
populations where Se status is well above the physio-
logical range for optimal activity of plasma glutathione
peroxidase and dietary Se intakes [59]. In those settings,
increased Se intake might not be beneﬁcial owing to high
baseline levels. Secondly, most studies available were
designed as cross-sectional surveys, and are therefore
subject to reverse causation and incidence/prevalence
biases. In general, there have been disappointing ﬁndings
from several costly clinical trials of antioxidant supple-
ments showing not only no health beneﬁts but potential
harms. The Selenium and Vitamin E Cancer Prevention
Trial (SELECT), conducted among 35,533 North American
men aged 50 and older, was prematurely stopped because
of lack of efﬁcacy of vitamin E and Se supplementation
(200 mg/d) in cancer prevention and because of a small,
though non-statistically signiﬁcant increase in the num-
ber of cases of adult onset diabetes in participants taking
only Se [41,42]. Thus, for ethical reasons it would be
difﬁcult to justify the initiation of additional RCTs of
micronutrient supplements; moreover, it is highly un-
likely that adequately powered trials of Se and cardio-
vascular outcomes will be initiated in the near future.
Nevertheless, from a public health perspective, it is
extremely important to understand the health effects of a
nutrient as selenium that is frequently supplemented.
Further research based on high-quality prospective
studies across different countries with variability in Se
intake and status may help deﬁne the full range of health
effects, beneﬁcial or detrimental, associated with
different ranges of Se exposure, as well as the optimal
ranges of Se intake and status for the general population
(i.e., ranges that are likely to maximize the health beneﬁts
while avoiding potential toxic effects). However, at pre-
sent the widespread use of dietary supplements such as
selenium for cardio-metabolic disease prevention in the
general population is not justiﬁed and should not be
encouraged [31].Functional foods and nutraceuticals in primary
prevention3
Introduction
“Let food be thy medicine and let thy medicine be food”Hippocrates of KosGreek Physician4th century BC3 The author of this section is Ferns G.Diet and cardiovascular disease
The relationship between dietary factors and cardiovas-
cular disease (CVD) has been a major focus of health
research for almost half a century. A small number of risk
factors appear to account for a very large percentage of
the attributable risk of CVD, and overall diet contributes
substantially [60] to lifestyle associated risk factors [61].
Epidemiological and clinical studies indicate that the risk
of CVD is reduced by a diet rich in fruits, vegetables,
unreﬁned grains, ﬁsh and low-fat dairy products, and
low in saturated fats and sodium [62] (Table 1). Other
foods such as mono- and polyunsaturated fats, bran,
nuts, plant sterols, and soy proteins have also been
shown to have a favorable effect on lipid proﬁle, blood
pressure [63,64], endothelial and platelet function and
the inﬂammatory response (Table 1). The potential
beneﬁts of entire diets, particularly the Mediterranean
diet [65], and whole foods [66] have also been exten-
sively studied. These studies have stimulated interest in
the potential cardio-protective effects of individual food
items, or components of these foods, such as antioxi-
dants. However, it is often difﬁcult to be sure whether
any single dietary component is responsible for the
cardio-protective effects, or whether this is due to the
entire combination of nutrients and dietary habits. The
conﬂicting results between the apparent protective ef-
fects of nutrients as part of normal dietary intake, and
the lack of effectiveness in trials of single nutrient sup-
plements, has led to a focus on the potential for whole
foods, or modiﬁed diets (e.g. those rich in fruit and
vegetables) as being protective against CVD [67]. Even
this is not entirely straightforward; the effects of fruit
and vegetables on cardiovascular risk are dose-
dependent, and may be related to the type of fruit, or
vegetable consumed [68].
Functional foods and nutraceuticals
Functional foods are deﬁned as foods that, in addition to
supplying nutrients, offer potential health beneﬁts that
can enhance the well-being of individuals. They “. affect
one or more target functions in the body, beyond their
nutritional effects, to either improve health and/or reduce
the risk of disease” [69], and should by several deﬁnitions,
be consumed as part of a normal food pattern, “. and not
as a pill, a capsule nor any form of dietary supplement.”
[70]. Some examples of functional food are shown in
Table 2. In Japan an approval process for functional foods
(Foods for Speciﬁed Health Uses, FOSHU) was established
in the 1980’s [71]. The criteria for the FOSHU approval
process are shown in Table 3.
The term nutraceutical was coined by DeFelice in the
early 1980’s [72], and it has subsequently been used
interchangeably with functional food to designate foods
for disease prevention and health promotion. DeFelice’s
original deﬁnition of nutraceuticals includes dietary sup-
plements [73] and these are explicitly excluded in most
deﬁnitions of nutraceuticals. An interest in nutraceuticals
Table 2 Practical examples of functional foods.
Deﬁnition Examples
A natural food, fruit or grain
which may or may not be
modiﬁed
e.g. Vitamin E-enriched
vegetable oils, vitamin
A-enriched, genetically
engineered, “golden” rice
A food to which a component
has been added
e.g. A spread with added
phytosterols
A food from which a component
has been removed or reduced
e.g. A yogurt with
reduced fat
A food in which one, or several
components, have been modiﬁed,
replaced or enhanced to improve
its health properties
e.g. A juice drink with
enhanced antioxidant
content, a yogurt with
added prebiotic or
probiotic
Table 3 Criteria for approval by the Japanese Ministry of Health,
Labour and Welfare.
FOSHU (Foods for Speciﬁed Health Uses) approval
Effectiveness in humans is clear
Absence of safety issue
Nutritionally appropriate ingredients (no excessive salt)
Compatibility with product speciﬁcation by the time of
consumption
Established quality control methods
Table 1 Potential cardiovascular protective effects of functional
foods.
Protective
mechanism
Functional food Active component
Lipid lowering Fruit and
vegetables
Fibre
Legumes Fibre and phytochemicals
Margarine Phytosterols
Nuts Omega-3 fatty acids,
ﬁbre and polyphenols
Oily ﬁsh Omega-3 fatty acids
Soy protein Genistein and daidzein
BP lowering Ginseng Ginsenosides
Grapes and
red wines
Grape polyphenols
Green and
black teas
Polyphenols
Legumes Fibre
Oily Fish Omega-3 fatty acids
Onion and garlic Quercetin
Whole grains Fiber and phytochemicals
Antioxidant Brazil nuts,
grains and seeds
Vitamin E, selenium
Grapes and
red wines
Anthocyanins, catechins,
cyanidins, ﬂavonols,
myricetin, resveratrol
and quercetin
Green leafy
vegetables
and fruits
Carotenoids, tocopherol,
tocotrienols, vitamin C,
ﬂavonoids, indoles, lutein
Soy proteins Genistein and daidzein
Tea (green and
black)
Polyphenols
Tomatoes Lycopene
Vegetable oils Tocopherols
Anti-
inﬂammatory
Fish Omega-3 fatty acids
Nuts, seeds,
and oils
Vitamin E
Legumes Polyphenols
Tea Catechins
Fruits and
vegetables
Quercetin
Grapes and
red wines
Anthocyanins, catechins,
cyanidins, ﬂavonols,
myricetin and quercetin
Endothelial
function
Citrus fruits
and vegetables
Vitamin C, polyphenols
Chocolate (dark) Flavonoid
Fish Omega-3 fatty acids
Grapes and
red wines
Anthocyanins, catechins,
cyanidins, ﬂavonols,
myricetin and quercetin
Nuts Omega-3 fatty acids,
polyphenols
Platelet
aggregation
Grapes and
red wines
Anthocyanins, catechins,
cyanidins, ﬂavonols,
myricetin and quercetin
1280 G. Assmann et al.for cardiovascular prevention was stimulated following the
reports of a close association between the consumption of
particular dietary factors, including those taken as sup-
plements (e.g. vitamin E) with measures of status, and
reduced cardiovascular event rate [74].Antioxidants, functional foods, nutraceuticals and
cardiovascular disease
The apparent conundrum of positive effects of whole diets
and negative outcomes of most supplement trials has been
particularly well debated in relationship to the role of
antioxidants in CVD prevention. Oxidative stress is a
disturbance in the pro-oxidant/antioxidant balance that
favors oxidation that appears to be involved in the etiology
of several chronic diseases including CVD [75]. Dietary
nutrients, both water soluble (e.g. vitamin C) and lipid
soluble (vitamins A and E), comprise an important
component of the antioxidant defences. Observational,
prospective cohort studies have suggested that a high di-
etary intake or supplementation of vitamin E is associated
with a lower risk of CVD and mortality. In vitro and in vivo
studies in experimental animal models [76] lent support to
the potential beneﬁts that vitamin E may have, but the
evidence from clinical intervention trials is essentially
negative [77]. The effects of antioxidant supplements (b-
carotene, vitamin A and vitamin E) on all-cause mortality
in primary and secondary prevention trials, may increase
mortality, and the potential role of vitamin C and selenium
on mortality needs further study [32,33]. Whilst one early
study has shown a reduction in myocardial infarction and
cardiac events [78], the majority of the other trials have
shown no positive effect. Furthermore in at least ﬁve trials,
antioxidant supplementation was associated with
increased all-cause mortality and two have shown higher
risk of fatal CHD (ATBC and CARET) [79,80]. Whilst these
Table 4 Stages in the assessment of functional foods.
Steps in process Examples of investigation
Assessment of
composition
Macronutrient (e.g. Fibre)
Micronutrient (e.g. Antioxidant)
Assessment of in
vitro properties
Antioxidant properties
Effects on signaling
Bioavailability and
pharmaco-kinetic
studies
Absorption
Tissue distribution
In vivo studies in
animal models
Pharmacokinetics
Toxicology
Intervention in disease models
Human studies Bioavailability
Safety
Observational
Intervention [Un-blinded;
placebo-controlled; double-blind,
randomized, placebo controlled
(surrogate end-point; clinical end
Functional foods 1281results do not invalidate the role of oxidative stress in CVD,
they do indicate that high dose supplementation with
antioxidant vitamins may not represent an optimal strat-
egy to prevent CVD in individuals at high risk of CVD.
Several factors may have contributed to confound the re-
sults of these clinical trials; these include the uncertainty
about the dose and form of the antioxidant for optimum
bioavailability; the composition of the mixture of antiox-
idant to be used, as antioxidants often work in synergy;
and the stage of the disease at which they are used (pri-
mary or secondary prevention) [81]. The off-target effects
of antioxidants may also be important, and for vitamin E
several pleiotropic properties have been reported [82].
Furthermore, CVD is a complex, multi-factorial and multi-
step disease, in which the off-target effects of antioxidants,
and functional foods more generally, may also be
important.point)]
4 The author of this section is Kromhout D.The complexity of deﬁning a functional food and the
beneﬁts of its deconstructed products
Health claims are often made for food in the absence of
the deﬁnitive clinical trial data that have been advocated
by DeFelice [72]. Whilst fruit juices contain antioxidants,
they also contain sugars, or other factors, that appear to
increase the risk of diabetes mellitus. It is therefore
difﬁcult to be sure about the overall cardiovascular ben-
eﬁts of fruit juice, and it is now recommended that fruit
juice should only contribute 1 of the daily portions of
fruit and vegetables. This report by Bassano and col-
leagues [83] illuminates a further important issue. The
beneﬁts of an entire functional food may not be mirrored
by the effects of its constituent individual macro and
micro-nutrients. Health claims have been made for these
components in the absence of a formal clinical trial
evaluation. Furthermore, within a particular category of
food, e.g. fruit, vegetable, nut, or legume; there may great
variations in biological activity. For example fruit juices
vary substantially in their in vitro antioxidant potency
[84] but their content of other potentially therapeutic
constituents (e.g. ﬁbre [85]) and the impact of conversion
from food to juice on the process of digestion and gly-
caemic index, which may also be important properties in
CVD prevention [86], are often disregarded. A further
important complexity relates to the preparation of
certain food products. Nuts are reported to have beneﬁ-
cial effects on CVD risk [87] and yet they, or their
deconstructed products (oils, nut milk and nut butter),
are consumed in several forms (e.g. salted, roasted,
ground) that may to some degree offset their beneﬁcial
effects. It should also be remembered that the intake of
functional foods may have an indirect effect on the
quality of the diet, by replacing other foods and hence
reducing the intake of dietary constituents that may in-
crease CVD risk. It is clearly important that any health
claim for a food is supported by a series of experimental
data, including double blind, placebo-controlled clinical
trials. The stages that may be used in the evaluation of apotential functional food, or nutraceutical are shown in
Table 4.
Conclusions
There is evidence from longitudinal cohort studies that
certain classes of food and dietary patterns are beneﬁcial
in primary prevention. The results of these studies have
led to the identiﬁcation of putative functional foods. The
mechanisms by which these foods exert these effects are
complex, but are probably related to the macro- and
micronutrient content of the food, and the displacement of
other constituents of the diet. The beneﬁts observed may
depend on the baseline risk factors, and state of existing
disease, be dose dependent, and may be affected by the
preparation of the food. The beneﬁts of functional food
have infrequently been reproduced by providing isolated
components of foods as supplements. It appears essential
that before health claims are made for particular foods,
in vivo studies are undertaken that demonstrate efﬁcient
absorption and beneﬁcial effects on the cardiovascular risk
proﬁle. Ultimately, randomized, double-blind, placebo-
controlled trials of clinical end-points are necessary to
establish clinical efﬁcacy.
Fish and ﬁsh oil4
Introduction
Fish, especially fatty ﬁsh, is a rich source of the omega-3
fatty acids eicosapentaenoic acid (EPA) and docosahexae-
noic acid (DHA). The intake of these fatty acids is inversely
related to fatal coronary heart disease (CHD). This com-
posite cause of death includes generally fatal myocardial
1282infarction (MI), cardiac arrest and sudden death. The GISSI-
Prevenzione trial showed, in posteMI patients, that an
additional amount of 900 mg/d EPA-DHA reduced CHD
death by 35% and sudden death by 45% [88]. Basic research
made clear that unstable vulnerable plaques are the main
cause of fatal MI. Ventricular tachycardia and ventricular
ﬁbrillation may cause cardiac arrest and sudden death
[89].
Several mechanisms of action may explain the protec-
tive effect of omega-3 fatty acids on fatal CHD [90]. EPA-
DHA reduce serum triglyceride levels and remnant lipo-
proteins. They also reduce inﬂammation and improve
endothelial function and vasodilatation. Together they
promote plaque stabilization. Omega-3 fatty acids inhibit
platelet aggregation and have a positive effect on blood
rheology and mitochondrial function. Finally, EPA-DHA
intake reduces the risk of severe arrhythmias and its
sequelae, i.e., cardiac arrest and sudden death, through the
enrichment of myocardial membranes with these fatty
acids.Fish consumption and fatal CHD
In the 1970s epidemiological studies showed that the
incidence of MI was 10 times lower among the Inuit
compared to Danes [91]. The Inuit consumed approxi-
mately 400 g of seafood per day, with an average of 14 g
per day of omega-3 fatty acids compared to 3 g per day
among Danes [92]. The difference between the Inuit and
the Danes in the intake of omega-3 fatty acids was re-
ﬂected in the fatty acid composition of their platelets.
Differences were also observed in hemostatic factors,
bleeding time and high-density lipoprotein (HDL)-choles-
terol levels [93]. To show that these associations are causal,
the British physiologist Hugh Sinclair put himself in 1977
on an Inuit diet for 100 days [94]. His bleeding time rose
from 3e5 to 50 min and substantial decreases were
observed in blood platelets, erythrocytes, pack cell volume
and haemoglobin. The triglyceride-rich very low-density
lipoprotein fraction fell and the HDL fraction increased
considerably. The results of this experiment are in accord
with those found in the comparative studies among Inuit
and Danes.
Based on the ecological studies among the Inuit and
Danes and those comparing farmers and ﬁshermen in
Japan, Kromhout et al. hypothesized that ﬁsh consumption
could reduce CHD mortality [95]. In 1985 in the Zutphen
Study, a prospective cohort study in the Netherlands
among originally 852 middle-aged men, these authors
showed that eating ﬁsh once or twice a week was associ-
ated with a 50% lower risk of 20-year CHD mortality
compared to those who did not eat ﬁsh. Kromhout
deduced from these studies that two different mechanisms
could be responsible for the association between ﬁsh
consumption and CHD [96]. He hypothesized an acute ef-
fect on fatal CHD in cultures with a low level of ﬁsh con-
sumption and a chronic effect in cultures with a high level
of seafood consumption (Fig.).The association between seafood consumption and fatal coronary ar-
tery disease. Reproduced with permission from reference [96].
The hypothesis that a low level of ﬁsh consumption
may reduce fatal CHD was also tested in a small prospec-
tive cohort study of 272 elderly men and women in the
Netherlands [97]. In this study 60% of the participants
habitually consumed ﬁsh and 40% did not. In line with the
results of the Zutphen Study, also this study showed that
people who ate ﬁsh approximately once a week had a 50%
lower risk of 17-year CHD mortality. The associations of
fatty ﬁsh and lean ﬁsh intake with fatal CHD were studied
in the Seven Countries Study cohorts from Finland, the
Netherlands and Italy [98]. In this study 3000 men aged
50e69 were followed for 20 years. Men who consumed
fatty ﬁsh (e.g. herring and mackerel) had a 34% lower risk
of fatal CHD compared to those who did not eat ﬁsh. The
intake of lean ﬁsh (e.g. plaice, codﬁsh) was not associated
with CHD mortality. Finally, we observed in the Dutch
MORGEN project with 21,342 men and women aged
20e65 at entry that even a low level of ﬁsh consumption
and a low intake of EPA-DHA was associated with a 50%
lower risk of 10-year CHD mortality but not with non-fatal
MI [99].
The most recent meta-analysis on ﬁsh consumption and
CHD mortality included 17 cohorts with 315,812 partici-
pants and an average follow-up of 15.9 years [100].
Compared to people with the lowest ﬁsh consumption, a
ﬁsh consumption of once a week was associated with a
16% (Relative Risk (RR) Z 0.84; 95%CI 0.75e0.95) lower
risk of fatal CHD. Similar RRs were obtained for those who
ate 2e4 or at least 5 servings per week. For Western
countries, the strongest associations were obtained in the
Netherlands and the USA. This was possibly due to the low
level of ﬁsh consumption in these countries and to the
relatively large number of persons who did not eat ﬁsh.
Therefore, in these countries the strongest contrast was
observed between people who consumed ﬁsh once a week
compared to non-ﬁsh eaters.
There is only one secondary prevention trial that tested
the effect of an additional amount of fatty ﬁsh on fatal
CHD. The diet and re-infarction trial (DART) was carried
out in 2000 cardiac patients who were advised to eat oily
ﬁsh at least twice a week and were followed for 2 years
[101]. The results of the trial showed that an additional
amount of two fatty ﬁsh dishes per week reduced fatal
G. Assmann et al.
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spective cohort studies provide convincing evidence that
eating fatty ﬁsh at least once a week or lean ﬁsh twice a
week reduces fatal CHD risk.
Fish consumption, omega-3 fatty acids, cardiac arrest
and sudden death
Less studies have been published on the relation between
ﬁsh consumption and cardiac arrest or sudden death. A
population-based caseecontrol study from the USA
showed that eating fatty ﬁsh once a week was inversely
associated with cardiac arrest [odds ratio (OR) Z 0.5; 95%
CI 0.4e0.8) and even stronger with red blood cell mem-
brane omega-3 fatty acids (OR Z 0.3; 95% CI 0.2e0.6)
[102]. Also in a nested caseecontrol study carried out in
the Physicians Health Study from the USA, the baseline
blood level of omega-3 fatty acids was strongly inversely
related to sudden death (RR Z 0.19; 95% CI (0.05e0.71)
[103].
The association of the long-term ﬁsh consumption and
sudden cardiac death was investigated in the Zutphen
Study [104]. Long-term fatty ﬁsh consumption was
inversely associated with sudden coronary death in the
subsequent 40 years, and men who consumed fatty ﬁsh
had a 54% lower risk (RR Z 0.46; 95%CI 0.27e0.78) than
those who did not eat fatty ﬁsh. Lean ﬁsh consumption
was not associated with sudden coronary death. The
Physicians Health Study showed that men who consumed
one ﬁsh meal per week had a 52% lower risk of sudden
cardiac death (RR Z 0.48; 95%CI 0.24e0.96) compared
with those who consumed ﬁsh less than once a month
[105]. The results from the caseecontrol and the pro-
spective cohort studies suggest that eating ﬁsh once or
twice a week e corresponding to an intake of about
200 mg/d EPA-DHA e compared to eating no ﬁsh, is
associated with a lower risk of cardiac arrest and sudden
death.
Omega-3 fatty acid supplementation trials and fatal CHD
For the GISSI-Prevenzione trial more than 11,000 patients
with a recent MI (<3 months ago) were randomized to an
additional amount of 900 mg EPA-DHA per day and were
followed for 42 months [88]. The control group did not
receive a placebo. The additional amount of EPA-DHA
reduced cardiovascular disease incidence by 20%, cardiac
death by 35% and sudden death by 45%. The trial had an
open label design and was liable to performance bias (i.e.
differential behavior of participants between intervention
and control groups or differential care provided by physi-
cians). Therefore results from randomized, double-blind
placebo-controlled trials were needed.
Using information from prospective cohort studies and
controlled trials published up to 2002, we designed a
randomized, double-blind, placebo-controlled trial, the
Alpha Omega Trial, to test the effect of omega-3 fatty acids
on major cardiovascular events [106]. The trial has a 2  2
factorial design and evaluated the effect of an additionalamount of EPA-DHA and of the plant-oil based alpha-
linolenic acid (ALA). The results from the prospective
cohort studies had suggested that in cultures with a low
level of ﬁsh consumption, an intake of 200 mg/d of EPA-
DHA was associated with a signiﬁcantly lower risk of
fatal CHD and sudden death. The DART and the GISSI-
Prevenzione trial suggested that, taking non-compliance
into account, a dose of approximately 600 mg EPA-DHA
per day was effective. We took the average of 400 mg/d,
as the amount to be tested in the Alpha Omega Trial. For
ALA, we used a dose of 2 g/d, equal to the recommended
daily intake.
Between 2002 and 2006, we randomized from 32
centers in the Netherlands 4837 posteMI patients aged
60e80 who had had an MI up in the previous 10 years. The
patients received either a margarine enriched with an
additional amount of EPA-DHA or ALA or a combination of
both, or placebo margarine. The fatty acid composition of
the margarines were identical with the exception of the
omega-3 fatty acids. In the experimental margarines, the
neutral fatty acid oleic acid was replaced by the required
amounts of either EPA-DHA, ALA or a combination of both.
The margarines were identical in color, taste, odour and
texture. The patients were followed for an average of 41
months, during which 671 developed a major cardiovas-
cular event (fatal and nonfatal cardiovascular diseases, and
revascularization). The additional amount of EPA-DHA and
ALA did not reduce the rates of major cardiovascular
events, fatal CHD or ventricular-arrhythmia-related events
(placement of a cardioverter-deﬁbrillator, cardiac arrest
and sudden death).
Several meta-analyses of randomized controlled trials
have been published. Two meta-analyses published
before 2010 showed that EPA-DHA reduced fatal CHD
signiﬁcantly by 20% and sudden death non-signiﬁcantly
by approximately 15% [107,108]. The three trials with
posteMI patients published in 2010 and the recently
published trial in patients with multiple risk factors, did
not show an effect of extra EPA-DHA on fatal CHD
[90,109]. Two meta-analyses were published in 2012, one
including 14 randomized, double-blind placebo-
controlled trials [110] and the other 20 randomized
clinical trials including those with a patient history of
cardiovascular disease, presence of implantable
cardioverter-deﬁbrillator, with omega-3 fatty acid sup-
plementation through ﬁsh oil supplements and dietary
counseling [111]. In these meta-analyses the daily dose of
EPA-DHA ranged from 0.4 to 4.7 g/day and the follow-up
periods ranged from 1.0 to 4.7 years. Omega-3 fatty acid
supplementation did not reduce major cardiovascular
events but did reduce fatal CHD signiﬁcantly by
approximately 10% in both meta-analysis, if no adjust-
ment was made for multiple comparisons. Supplemen-
tation with EPA-DHA reduced sudden death by 7% in the
meta-analysis by Kwak et al. and by 13% in the meta-
analysis by Rizos et al., and therefore in both cases not
to a signiﬁcant extent [110,111].
An intriguing question to be answered is why did an
additional amount of EPA-DHA in the early clinical trials
5 The authors of this section are Merino J and Masana L.
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and why did the recent ones show no effect? One of the
explanations could be the earlier mentioned confounders
due to the open label design of the early trials. Another
explanation could be that the patients in the recent trials
were very well treated not only by antithrombotic drugs as
in the early trials, but also by state-of-the-art treatment
with antihypertensive drugs and statins [112]. Compared
to the recent trials, the treatment level of statins was low
(29%) in the GISSI-Prevenzione trial [88]. Therefore, we
carried out a subgroup analysis in non-statin users in the
Alpha Omega Trial [113]. The average LDL cholesterol level
was 0.8 mmol/l higher in the non-statin users compared to
statin users, and the LDL cholesterol level of the non-statin
users in the Alpha Omega Trial was similar to that of the
participants in the GISSI-Prevenzione trial (3.38 vs.
3.55 mmol/l). An additional amount of 400 mg/d EPA-DHA
was not enough to reduce major cardiovascular events in
non-statin users, but an additional amount of 400 mg/
d EPA-DHA in combination with 2 g/d ALA reduced the
major cardiovascular events by 54% (hazard ratio Z 0.46;
95% CI 0.21e1.01, PZ 0.051). These results suggest that the
low level of statin treatment could be the major reason for
the protective effect of EPA-DHA on major cardiovascular
events observed in the GISSI-Prevenzione trial.
Compared to the Alpha Omega Trial, the absolute risk in
the GISSI-Prevenzione trial was almost twice as high for
fatal CHD and three times higher for sudden death [90].
This could be another explanation for the positive results
in the GISSI-Prevenzione trial and the negative results in
the Alpha Omega Trial. Therefore we selected in the Alpha
Omega Trial a subgroup of patients who had had not only
an MI, but who also had diabetes [114]. These patients had
a similar rate of fatal CHD as the patients with a recent MI
in the GISSI-Prevenzione trial. In the patients with the
double burden of MI and diabetes, an additional amount of
400 mg/d EPA-DHA reduced the composite endpoint of
ventricular-arrhythmia-related events by 42% and there-
fore not to a signiﬁcant extent (hazard ratioZ 0.58; 95%CI
0.24e1.39); conversely an additional amount of 2 g/d ALA
signiﬁcantly reduced this endpoint by 53% (hazard
ratio Z 0.47; 95%CI 0.18e1.24). The combination of
400 mg/d EPA-DHA plus 2 g/d ALA was able to reduce
ventricular-arrhythmia-related events by 84% (hazard
ratio Z 0.16; 95%CI 0.04e0.69). The combination of extra
EPA-DHA plus ALA reduced also the composite endpoint of
ventricular-arrhythmia-related events plus fatal MI by 72%
(hazard ratio Z 0.28; 95%CI 0.11e0.71). These results
suggest that omega-3 fatty acids protect against severe
arrhythmias and fatal MI only in high-risk patients.
Fish or ﬁsh oil supplements?
Prospective cohort studies showed that eating ﬁsh once a
week vs. less than once a month was associated with a
signiﬁcantly lower risk of fatal CHD. The protective effect
of ﬁsh was conﬁrmed in a randomized controlled trial in
cardiac patients. In contrast to the earlier trials, recent
trials did not ﬁnd a protective effect on fatal CHD of extraEPA-DHA in trials with ﬁsh oil supplements. Based on
these results I recommend to both individuals without and
with a history of cardiovascular disease to eat fatty ﬁsh at
least once or lean ﬁsh twice a week. The advantage of this
recommendation above the use of ﬁsh oil supplements is
that ﬁsh, in particularly fatty ﬁsh, is a rich source not only
of the omega-3 fatty acids EPA and DHA, but also of, for
example minerals such as potassium and calcium, and
vitamins such as vitamin D and vitamin B12. However, ﬁsh
is not a panacea for CHD prevention. The largest risk
reduction will be obtained if the recommended ﬁsh con-
sumption will be a component of a nutritionally adequate
diet.
Is it useful to recommend phytosterol-enriched foods to
patients already taking lipid-lowering drugs?5
Introduction
Plant sterols and stanols
Phytosterols (PSs) are non-nutritive compounds that are
structurally analogous to cholesterol with the same
function in plants that cholesterol has in animals. There
are more than 250 different phytosterols, including pure
sterols (PSRs) and stanols (PSNs), which are the saturated
form of sterols. Common dietary sources of PSRs are
plant-based foods that are rich in stigmasterol, b-sitos-
terol and campesterol, all members of the triterpene
family [115]. Phytostanols are found naturally at lower
concentrations than sterols and can be produced by the
hydrogenation of PSRs. Due to large differences in the
consumption and composition of vegetables throughout
the world, the dietary intake of plant sterols ranges from
160 mg/dl in Britain to 375 mg/day in Japan; populations
following vegetarian diets have been reported to intake
more than 600 mg/dl. Typically, the dietary intake of PSN
is approximately 50 mg/day. Vegetables with a high
percentage in PSs include vegetable oils, nuts, seeds, le-
gumes and whole-grains. Molluscs (oyster 264 mg/
100 g), crustaceans (lobster 137 mg/100 g) and egg yolks
(95 mg/100 g) are the most important non-vegetable
sources of PS.
The precise PSR/PSN mechanism of action is partially
understood. PS shave been shown to be effective in
reducing the absorption of both dietary and biliary
cholesterol from the intestinal tract by displacing choles-
terol from micelles, hence limiting the intestinal solubility
of cholesterol and decreasing the hydrolysis of cholesterol
esters in the small intestine. Cholesterol absorption is
regulated by controlling both in ﬂux and efﬂux. The uptake
of cholesterol from micelles into intestinal mucosal cells is
mediated by Niemann-Pick C1-Like 1 protein (NPC1L1),
which is partially inhibited by PSs [116]. The efﬂux of
cholesterol is determined by adenosine triphosphate-
binding cassette transporter proteins (ABCG5 and
ABCG8), and the up-regulation of these proteins decreases
net absorption by increasing cholesterol efﬂux. Moreover,
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esteriﬁcation inside the enterocyte is less efﬁcient for PSs
than for cholesterol [117]. The partial inhibition of
cholesterol absorption by the above mechanisms produces
a state of relative cholesterol deﬁciency, which is followed
by an up-regulation of cholesterol biosynthesis and LDL-
receptor activity.
Phytosterol-enriched functional foods
The production of PSR- and PSN-fortiﬁed food has
become popular because of the ability of these com-
pounds to decrease LDL cholesterol concentrations. The
ﬁrst description of the use of phytosterol-enriched
foods is from 1977. Lees et al. tested a commercial
preparation derived from soybean oil (3 g/d) and
observed a signiﬁcant decrease in LDLc after consump-
tion of this preparation [118]. Nine years later, in 1986,
Heinemann et al. reported the ﬁrst description of the use
of plant stanols to lower plasma cholesterol [119]. These
investigators showed that dispersed sitostanol in sun-
ﬂower oil at a dose of 1.5 g/day lowered LDLc by 15% in
hypercholesterolaemic adults. Both sterols and stanols
are frequently used in esteriﬁed forms because this form
increases their solubility and allows for their incorpo-
ration into lipid-based foods, such as margarines, yo-
ghurts, mayonnaise, milk, salad dressings and snacks
bars. Recent studies have investigated the consumption
of regularly consumed foods enriched with phytosterols
esters, concluding that these products have been
shown to be an effective means of reducing total
cholesterol and LDLc in adults and children with
hyperlipidaemia [120]. Many randomized controlled
trials (RCT) have clearly established that LDL
cholesterol plasma concentrations are reduced by
approximately 10% with PSR/PSN fortiﬁed-foods in a
dose-dependent manner, reaching a maximum plateau
at approximately 1.5e2 g per day. In this review, we
focus on the effect of PSRs/PSNs in conjunction with
lipid lowering drugs.
Effect of phytosterols add-on lipid lowering treatment
Statins
Statins (3-hydroxy-3-methyl-glutaryl coenzyme-A
reductase inhibitors) are the most effective lipid-
lowering medications for the prevention of coronary ar-
tery disease. These compound function by blocking the
limiting enzyme HMG CoA reductase, leading to an in-
crease in the number of LDL receptors and augmenting
LDL plasma clearance. To balance this inhibition in
cholesterol synthesis, there is a concomitant increase in
intestinal cholesterol absorption. Therefore, PSRs/PSNs
have been speculated to play a synergistic role with
statins. The ﬁrst study on the effect of combining PSN
supplementation with statins was conducted in 1994 by
Vanhanen et al. In a speciﬁc cohort of statin treated
hypercholesterolaemic subjects (on increasing pravasta-
tin doses from 40 to 80 mg/d), the addition of 1.5 g/day
of a sitostanol ester-enriched mayonnaise was associatedwith an additional 10.8% decrease in LDLc after the
follow-up period [121]. More marked reductions were
observed in patients with coronary heart disease or fa-
milial hypercholesterolaemia, the general population or
postmenopausal women who were receiving stable
statin lipid-lowering treatment. In these studies, plant
stanol esters at a dose of 2e3 g/day lowered LDLc by an
additional 16%e20% compared to statins alone, although
these studies were open labeled.
The best evidence for the beneﬁcial effect of PSs in
patients undergoing statin treatment has come from
different double-blind, randomized, placebo-controlled
trials, as shown in Table 5. Plant sterol esters were used
in 10 studies [122e131] and plant stanol esters in 14
[121e123,125e128,132e138], each administered in doses
of 1.5e3 g/day for 4e26 weeks; one study had a long term
follow-up of 85 weeks [123]. Reductions in LDLc ranged
from 4% to 15%. In these studies, PSR supplementation was
associated with an additional reduction in total cholesterol
ranging from 5% to 11% and in LDLc ranging from 8% to
17%. Similarly, dietary PSN supplementation in statin
treated patients was related to a signiﬁcant decrease of
between 4% and 11% in total cholesterol and 6% and 16% in
LDLc. Data from a previous meta-analysis of 8 randomized
controlled trials that included more than 300 statin-
treated hypercholesterolaemic patients concluded that
the addition of PSRs/PSNs at doses of 1.7e6g/day signiﬁ-
cant lowered both total cholesterol (14 mg/dl) and LDLc
(13 mg/dl) compared to statin use alone [120]. No signif-
icant impact on either HDLc or triglycerides has been
shown. Regarding the question about the differential effect
on LDLc by PSNs or PSNs, previous systematic reviews
have grouped plant sterols and plant stanols together
without regard to potential differences in comparative
efﬁcacy [120,139]. Plant sterols have a higher bioavail-
ability than plant stanols [129,134], which may suggest
differences in the degree of cholesterol displacement in
the intestinal micelles. A meta-analysis of 14 randomized
controlled trials evaluating the effect of plant sterols vs.
plant stanols at doses of 0.6e2.5 g/day in healthy patients
and patients with hypercholesterolaemia showed no
signiﬁcantly different effects between the two on total
cholesterol, LDL cholesterol, HDL cholesterol, or triglycer-
ide levels [25]. It appears that the overall results from
many randomized controlled studies support that PSRs/
PSNs maintain their LDL lowering capacity when admin-
istered with statins. No safety concerns were reported in
these medium-length studies. Moreover, no major differ-
ences were observed between PSRs and PSNs.
Ezetimibe
Ezetimibe is the ﬁrst member of a new pharmacological
family for the treatment of hypercholesterolaemia devel-
oped since the discovery of statins. The lipid-lowering
mechanism of ezetimibe is mediated by cholesterol ab-
sorption inhibition. Although the molecular drug target
was initially under controversy, today it is generally
acknowledged that ezetimibe inhibits cholesterol absorp-
tion by binding an extracellular loop of NPC1L1. Ezetimibe
Table 5 Characteristics of studies in already statin treated patients with the additional effect of phytosterols on serum lipid parameters.
Author(s),
(reference),
year, (n)
Study
design
Population Follow-
up
Statin dosing PSR/PSN dosing Changes in LDLc
after follow-up
Concurrent
diet
Hallikainen
et al.
[138]
2011
(n Z 24)
Double-
blinded
parallel
Type 1 Diabetes and
controls
4
weeks
Stable doses of
atorvastatin (n Z 4),
rosuvastatin (n Z 2)
and simvastatin
(n Z 18)
Vegetable oil-based test
spreads (3 g/d PSN)
(n Z 12)
3.8%a Usual diet
Kelly et al.
[126]
2011
(n Z 30)
Double
blinded
parallel
Hypercholesterolaemia 85
weeks
Stable statin
treatment for several
years
PSR enriched margarine
(2.5 g/d) (n Z 11) PSN
enriched margarine (2.5 g/
d) (n Z 8)
PSR:
9.6%a
PSN:
9.7%a
Usual diet
De Jong
et al.
[122]
2008
(n Z 41)
Double-
blinded
parallel
Hypercholesterolaemia 16
weeks
Stable doses of
atorvastatin,
simvastatin or
pravastatin
PSR ester-enriched
margarine (2.5 g/d)
(n Z 15) PSN ester-
enriched margarine (2.5 g/
d) (n Z 15)
PSR:
7.6%
PSN:
12.2%a
Usual diet
Fuentes
et al.
[124]
2008
(n Z 30)
Double-
blinded
crossover
Familial
Hypercholesterolaemia
4
weeks
Atorvastatin or
simvastatin 40 mg/d
PSR ester-enriched
margarine (2.5 g/d)
(n Z 30)
7.1% 4 dietary
low-fat
interventions
De Jong
et al.
[123]
2008
(n Z 54)
Double-
blinded
parallel
Hypercholesterolaemia 85
weeks
Stable doses of
atorvastatin,
simvastatin,
pravastatin or
rosuvastatin
PSR ester-enriched
margarine (2.5 g/d)
(n Z 18) PSN ester-
enriched margarine e
(2.5 g/d) (n Z 19)
PSR:
8.7%
PSN:
13.1%a
Usual diet
Takeshita
et al.
[131]
2008
(n Z 44)
Double-
blinded
parallel
Hypercholesterolaemia 12
weeks
Pravastatin 10 mg/d PSR dissolved in DAG oil
(0.4 g/d) (n Z 14)
5.1%a Usual diet
Castro-
Cabezas
et al.
[134]
2006
(n Z 20)
Single-
blinded
parallel
Hypercholesterolaemia 6
weeks
Maximal dose of
statins (A80 or S80)
for at least 6 months
before inclusion
PSN enriched margarine
(3 g/d) (n Z 11)
15.6%a Intensive
dietary
intervention
Goldberg
et al.
[136]
2006
(n Z 26)
Double-
blinded
parallel
Hypercholesterolaemia 6
weeks
Stable statin doses Soy PSN tablets (1.8 g/d)
(n Z 13)
6.3% American
Heart
Association
Healthy diet
Hallikainen
et al.
[125]
2006
(n Z 76)
Double-
blinded
crossover
Hypercholesterolaemia 20
weeks
Stable statin doses PSN and PSR oil based
spreads (2 g/d) (n Z 39)
PSR:
9.6%a
PSN:
6.6%a
Usual diet
Cater et al.
[135]
2005
(n Z 10)
Double-
blinded
crossover
Hypercholesterolaemia
with CHD
8
weeks
Stable doses of
atorvastatin or
simvastatin
PSN ester-enriched
margarine (3 g/d)
14.9%a Low
saturated fat
and
cholesterol
diet
Ketomaki
et al.
[127]
2004
(n Z 3)
Double-
blinded
parallel
Family with FH,
including homozygous
child
157
days
LDL apheresis once
per fortnight
PSN and PSR ester-
enriched spread (2 g/
d both) (n Z 1 HoFH)
PSR:
17.4%a
PSN:
6.5%
Low-fat diet
Amundsen
et al.
[132]
2004
(n Z 57)
Open
labeled
Familial
Hypercholesterolaemia
26
weeks
Same doses of statins
during the whole
study period
PSN ester-enriched spread
(1.76 g/d) (n Z 20)
11.2%a Usual diet
Ketomaki
et al.
[128]
2004
(n Z 5)
Double-
blinded
crossover
Familial
hypercholesterolaemia
4
weeks
Stable statin doses,
A80 (n Z 3) A20
(n Z 1) L60 (n Z 1)
PSN and PSR rapeseed oil
spread (2 g/d)
PSR:
14.5%a
PSN:
16.4%a
Usual diet
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Author(s),
(reference),
year, (n)
Study
design
Population Follow-
up
Statin dosing PSR/PSN dosing Changes in LDLc
after follow-up
Concurrent
diet
Gylling
et al.
[137]
2002
(n Z 11)
Open
labeled
crossover
hypercholesterolemic
coronary patients
16
weeks
Stable statin doses
(S20). Cholestyramine
8 g/d was added for
the last 8 weeks
PSN ester-enriched
margarine (2.25 g/d)
(n Z 11)
13%a Low-fat low-
cholesterol
diet
Simons
et al.
[130]
2002
(nZ 154)
Double-
blinded
parallel
Hypercholesterolaemia 4
weeks
Cerivastatin 400 mg PSR ester-enriched
margarine (2 g/d) (nZ 37)
6.1% American
Heart
Association
diet step 1
Neil et al.
[129]
2001
(n Z 62)
Double-
blinded
crossover
Hypercholesterolaemia 8
weeks
Stable statin doses PSR fortiﬁed fat spread
(2.5 g/d) (n Z 31)
10%a Usual diet
Blair et al.
[133]
2000
(nZ 167)
Double-
blinded
parallel
Hypercholesterolaemia 8
weeks
Stable doses of
atorvastatin,
simvastatin,
pravastatin or
lovastatin
PSN enriched spread (3 g/
d) (n Z 83)
10%a Usual diet
Vanhanen
et al.
[121]
1994
(n Z 14)
Double-
blinded
parallel
Hypercholesterolaemia 6
weeks
Increaseing doses of
pravastatin from 40 to
80 mg/d
Sitostanol ester-enriched
mayonnaise (1.5 g/d)
(n Z 7)
10.8%a Usual diet
PSR: phytosterols, PSR phytostanol.
a p-Value <0.005 compared with the baseline lipid levels.
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preventing it from chaperoning the transport of choles-
terol from the plasma membrane to the endoplasmic re-
ticulum. Therefore, PSRs/PSNs could be considered
mechanistic competitors. To address this issue, two
important studies were conducted to evaluate if the
combination of ezetimibe and phytosterols was more
effective than ezetimibe alone in altering cholesterol
metabolism [140,141]. Jakulj et al. ﬁrst assessed this
question in a double-blind, placebo-controlled, crossover
study in which 40 subjects with mild hyper-
cholesterolaemia received 10 mg/d ezetimibe and either
25 g/d of a spread containing phytosterols (2 g/d) or 25 g/
d of a control spread. There were also two more passive
study arms in which subjects ate 25 g/d of a spread con-
taining phytosterols (2 g/d) without receiving ezetimibe or
the same amount of a control spread without ezetimibe.
The authors concluded that the LDLc reducing effect of the
combination (25%) did not signiﬁcantly differ from that the
ezetimibe monotherapy (22%) [140]. In contrast, Lin et al.
enrolled 21 mildly hypercholesterolaemic subjects in a
double-blind, placebo-controlled, triple-crossover study in
which individuals received a phytosterol-controlled diet
plus (A) a ezetimibe placebo and a phytosterol placebo, (B)
10 mg/d ezetimibe and a phytosterol placebo or (C) 10 mg/
d ezetimibe and 2.5 g phytosterols for 3 weeks each. The
authors observed that the addition of PSs to ezetimibe
signiﬁcantly enhanced the effects of ezetimibe, including
lower intestinal cholesterol absorption, greater faecalexcretion and signiﬁcant decreases in plasma LDLc. The
authors discussed that the mechanism of PS actions differs
from ezetimibe, because it has been observed that phy-
tosterols may act by substituting cholesterol from intesti-
nal micelles and enterocytes rather than by blocking the
molecule mediating cholesterol absorption NPC1L1 [141].
On the other hand, ezetimibe blocks phytosterol absorp-
tion, which has been considered a controversial safety
issue.
Fibrates
Patients with mixed dyslipidaemias (increased LDLc and
triglycerides and low HDLc) could beneﬁt from a combi-
nation of lipid-modifying drugs, such as ﬁbrates. The
pharmacological mechanisms of ﬁbrates are mediated by
PPARa activation. Several animal and human studies have
shown no interactions between PSRs/PSNs and ﬁbrates on
LDL cholesterol metabolism. Clinical studies have shown
an increase in the hypocholesterolaemic effect of PSRs/
PSNs added to ﬁbrates. On the other hand, their effects on
lipid proﬁles are complementary; PSRs/PSNs act on LDL
cholesterol, whereas ﬁbrates modulate HDL and tri-
glycerides concentrations, leading to global lipid control
[142].
Bile acid sequestrant resins
The primary mechanism by which humans remove excess
cholesterol is catabolism into bile acids. Approximately
6 The authors of this section are Rozza F and Trimarco B.
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reabsorbed in the distal digestive tract. Bile acid seques-
trant resins (BASRs) induce bile acid precipitation, and
these acids are not able to be reabsorbed in the distal
ileum and are excreted into the faeces. Not enough data
are available to determine the impact of BASRs on PSRs/
PSNs. BASRs interact with lipophilic substances that
interfere with intestinal phytosterols. On the other hand,
dietary PSRs but not PSNs have been suggested to suppress
bile acid synthesis, most likely by altering the cholesterol-
lowering efﬁcacy of BASRs [142].
N-3 fatty acids
Fish oils rich in long-chain PUFAs (N-3) can reduce circu-
lating triglycerides and raise HDLc. The combination of
both phytosterols and N-3 fatty acids results in a com-
plementary beneﬁcial effect on the lipid proﬁle. Accord-
ingly, in a single-blinded crossover study in which 21
moderately hyperlipaemic subjects were randomized to 4
experimental isoenergetic diets for 4 weeks each, LDLc
signiﬁcantly decreased by 13% after supplementation with
ﬁsh oil fatty acid esters of plant sterol. A recent study
provided hypercholesterolaemic children with a daily dose
of an emulsiﬁed preparation containing plant sterols esters
(1300 mg), ﬁsh oil (providing 1000 mg of eicosapentaenoic
acid [EPA] plus docosahexaenoic acid [DHA]) and vitamins
B12 (50 mg), B6 (2.5 mg), folic acid (800 mg) and coenzyme
Q10 (3 mg) for 16 weeks. In these children, a signiﬁcant
decrease in both total cholesterol and LDLc of 15% and 10%,
respectively, was observed [143]. Independent of the direct
effect on cholesterol metabolism, several mechanisms
have been proposed to explain how N-3 PUFAs might
beneﬁcially affect risk factors implicated in the patho-
genesis of atherosclerosis and thrombotic disease. These
mechanisms include improving vascular reactivity,
decreasing platelet aggregation, lowering plasma tri-
glycerides, decreasing blood pressure, preventing ar-
rhythmias and reducing inﬂammation.
Niacin
A complementary effect of niacin and PSRs/PSNs on lipid
proﬁles has been shown that is similar to the effects
described for ﬁbrates. In ApoE knockout mice, niacin has
been shown to increase the lipid-lowering effect of PSRs/
PSNs and to slow atherosclerosis progression.
Clinical indications
Reducing elevated LDLc is a key public health challenge,
and dietary modiﬁcation is the ﬁrst step toward improving
serum lipid levels. In response to the growing evidence
supporting the signiﬁcant cholesterol lowering effect of
phytosterol-enriched foods, the National Cholesterol Edu-
cation Program (NCEP) Adult Treatment Panel III (ATPIII)
guidelines recommended the inclusion of 2g/day of phy-
tosterols in the diet along with other dietary modiﬁca-
tions, such as decreasing the intake of saturated fat (<7% of
daily calories), trans-fat (less than 2%) and dietary
cholesterol (<200 mg/day) [144]. These recommendationsare also endorsed by other scientiﬁc organisations, such as
the European Atherosclerosis Society (EAS) [144].
PSR/PSN supplementation is indicated in individuals
with low cardiovascular risk and high cholesterol for
whom drug therapy is not indicated or is optional. How-
ever, in high-risk patients for whom drug therapy is
mandatory, the indication is not clear. According to our
review, the evidence suggests that adding phytosterol
enriched foods to the diet of patients on lipid-lowering
therapy will result in an incremental LDL decrease of
approximately 10%, which is more than the effect of
doubling the statin dose [129,130,133,134]. Other groups of
patients who might beneﬁt from PSRs/PSNs are those who
refuse to take statins and those who stop statin therapy
because of adverse effects, which occur in up to 10% of
patients.Acknowledgments
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cardiovascular risk6
The 2012 European Guidelines (GL) on cardiovascular (CV)
disease prevention in clinical practice stress the role of LDL
cholesterol (LDL-c) and the target level to reach in subjects
with a different degree of CV risk, that is low, moderate,
high and very high risk. The GL also specify that there are
some pathological conditions (e.g. familial hyperlipidemia;
presence of kidney dysfunction; occlusive peripheral ar-
tery disease), which should also be considered as an
expression of very high CV risk and therefore need a
pharmacological treatment. On the contrary, in subjects
with low CV risk there is no strict indication to drug
therapy despite an LDL-c level up to 190 mg/dl. The last
suggestion is based on the observation that these subjects
show a low probability of developing a CV event. Never-
theless, according to the so called Rose paradox, it’s well
known that the large proportion of CV events occurs in
this population, since the individual risk is low but the
number of subjects carrying such a risk is very high, thus,
multiplying a small risk for a large number of subjects
there is a lot of events in the whole population.
However, there are some observations which can ac-
count for the suggestions of the 2012 European GL. In
particular, the consideration that the decision to treat
implies the use of statins, ﬁbrates etc. to the highest rec-
ommended dose or, at least, the highest tolerable dose, or
to combine two molecules with the objective to reach the
target LDL-c plasma concentration. The choice to start a
pharmacological treatment represents the conclusion of an
accurate evaluation of the expected beneﬁt and the pos-
sibility of adverse events. The results of large intervention
Functional foods 1289studies have clearly demonstrated that statins are able to
markedly improve cardiovascular prognosis in patients
with high and very high CV risk [145], but it is also well
documented that the magnitude of the beneﬁcial effect
depends on the basal conditions of the patients. In fact, the
slope of the correlation between LDL-c plasma concen-
trations and cardiovascular events calculated in primary
prevention studies is signiﬁcantly smaller as compared to
that recorded in secondary prevention trials, which
include patients at higher CV risk [145]. So, the question is:
treatment of patients with low LDL-c levels does allow a
signiﬁcant reduction of the incidence of CV events? In the
Anglo-Scandinavian Cardiac Outcomes Trial e lipid
lowering arm (ASCOT-LLA), patients with an average e or
lower than average e plasma cholesterol concentration
received 10 mg of atorvastatin/die. Despite the low
cholesterol level, treatment was able to reduce fatal and
non-fatal MI by 36% [146].
On the other hand, although statin-induced rhabdo-
myolysis has an incidence of less than 1 per 10,000
patient-years for monotherapy and increases sharply only
with the combination of two different statins or a statin
combined Wight a ﬁbrate, the discontinuation rate, mainly
due to the adverse events (AE) related to the lipid lowering
agents reaches the 30% level.
Thus, moving to patients with a low LDL c plasma level
and a low probability to develop CV events, the weighed
beneﬁt of LDL c reduction is reduced, while the probability
of AE remains unchanged. It’s not only a theoretical
speech, since it has been recently demonstrated that sta-
tins increase the risk of developing diabetes [147].
Although it has been recently demonstrated that this effect
parallels the cholesterol lowering action of statins, since
this risk increases by raising the dose of each statins [148]
or moving from a less to a more effective statin [149], this
observation has not changed the clinical practice in pa-
tients with moderate or high CV risk, since the expected
beneﬁt is greater than the possible negative consequences.
On the contrary, in patients with a low CV risk a greater
probability to develop diabetes should be taken into ac-
count and so, to balance this element, it is important to
look for something with a comparable beneﬁcial effect and
a very low probability to induce AE.
The solution may be represented by nutraceuticals,
which are concentrated forms of presumed bioactive
substances originally derived from foods but now present
in non-food matrix and used to enhance health in dosages
exceeding those obtainable in normal food.
The available nutraceuticals are a lot, but the choice
should rely on the evidence-based medicine, since the
knowledge that a natural substance exerts a beneﬁcial ef-
fects when introduced as food does not necessarily implies
that the administration at higher dose as a pharmaceutical
supplementation will induce the same effect. In fact, the
HOPE study has demonstrated that supplementation of
Vitamin E, that in foods is able to exert an antioxidant ef-
fect, do not modify cardiovascular prognosis [150].
Recently, Affuso and coworkers [151] investigated in a
double blind, placebo controlled study performed inhypercholesterolemic patients the effect of a nutraceutical
combination (red yeast rice, berberine and polycosanols)
on plasma lipids, endothelial function and insulin sensi-
tivity, and showed a signiﬁcant reduction (vs. controls) in
total cholesterol, LDL-c and triglycerides, with no change
in HDL-c.
This nutraceutical combination led to an improvement
in endothelial function, known to be impaired in patients
with dyslipidemia. Moreover, in patients with insulin
resistance (baseline HOMA index > 2.6) treatment with
such nutraceutical combination signiﬁcantly reduced
HOMA, and signiﬁcantly increased the QUICKI and
McAuley indices, thus indicating enhanced insulin
sensitivity.
In another study, patients with metabolic syndrome or
dyslipidemia not tolerating statins or not requiring the use
of statins were treated with the nutraceutical combination
tested by Affuso [151]. After a two-week running period
with a standard diet, patients were randomized to placebo
(n Z 662) or to the combination of nutraceuticals
(n Z 682) for 8 weeks of treatment. The results showed
20% reduction in total cholesterol plasma concentration,
25% reduction of LDL-c, 7% increase of HDL-c, 20% reduc-
tion of plasma triglycerides and a fall in diastolic blood
pressure, which in keeping with the observation by Affuso
may be ascribed to an improvement of endothelial func-
tion and insulin sensitivity. This interpretation is also
corroborated by the observation of a signiﬁcant reduction
in waist circumference. At the end of the treatment period,
the percentage of patients with metabolic syndrome was
signiﬁcantly reduced (from 70% to 35%) in the study group,
but not in the placebo group, thus suggesting a reduction
in the risk of developing CV events.
In the era of the evidence-based medicine it is required
that the improvement in cardiovascular prognosis induced
by a pharmacological treatment is supported by the evi-
dence obtained in large intervention placebo controlled
trial that such a therapy induces a reduction of cardio-
vascular mortality and non-fatal myocardial infarction and
stroke. However, in low risk patients it is very difﬁcult to
obtain data on hard end-points, since the low probability
to develop such events would require the enrollment of a
huge number of subjects and a very long follow-up to
reach a satisfactory statistical power. On the other hand, in
clinical practice the decision to start a pharmacological
treatment is based on the calculated cardiovascular risk of
the single patient. Thus, in order to assess the effect of
nutraceutical combination on cardiovascular prognosis
Izzo and coworkers [152] evaluated the change in Fra-
mingham risk score induced by nutraceutical treatment.
For this purpose, they excluded patients with diabetes
mellitus since the presence of this pathological condition
would have precluded the possibility to reduce the global
cardiovascular risk score. Looking at the baseline Fra-
mingham Risk Score versus the ﬁnal Framingham Risk
Score in single patients, it was clear that those treated with
nutraceuticals moved from higher baseline values to lower
values at the end of the follow-up, while in the placebo
group the Framingham risk score remained unchanged
Table 6 Change in lipid proﬁle and CV risk in patients treated with
atorvastatin or nutraceuticals.
Atorvastatin
(ASCOTT-LLA)
NUT (effects of NUT on
calculated FRS)
TC (mg/dl) 50 48
Ldl-c (mg/
dl)
45 43
HDL-c
(mg/dl)
1 þ5
TG (mg/dl) 30 43
CV risk (%) 36 35
TC: total cholesterol; LDL-c: LDL cholesterol; HDL-c: HDL choles-
terol; TG: triglycerides; NUT: nutraceuticals; CV risk: Reduction of
cumulative incidence of primary end point (fatal or non-fatal MI) in
patients treated with Atorvastatin vs placebo and Reduction of
calculated Framingham Risk Score in patients treated with NUTs vs
placebo.
7 The authors of this section are Riccardi G, Rivellese AA and Vetrani C.
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was a reduction of the Framingham risk score of 35%
which reached the statistically signiﬁcance level.
Putting together the changes in lipid parameters ob-
tained in the ASCOT-LLA and in the Izzo trial, it’s possible
to observe that the changes in total and LDL-c were quite
similar, while an increase in HDL-c was detected only
during treatment with the combination of nutraceuticals
and was associated with a reduction in plasma triglyceride
concentration greater than that observed in the
atorvastatin-treated group (Table 6).
It is interesting to note that the reduction in the Hazard
Ratio (i.e. the probability of developing CV events) ob-
tained in the ASCOT-LLA study (primary end point: fatal or
non-fatal MI) was 36%, which is very similar to the
reduction in Framingham risk score observed in the Izzo
study (35%) (Table 6).
Conclusion
International Guide Lines for cardiovascular prevention
have been traditionally based on the results of random-
ized, placebo controlled large intervention trial, however
more recently there is a general consensus that the results
of registers and large studies performed in the real word
should be taken into consideration for the appraisal of
guide lines. This concept seems to ﬁt with the use of
nutraceuticals in the management of dyslipidemia in
subjects at low CV risk which may allow the reduction of
cardiovascular events in the general population. Further-
more, the studies performed following the suggestions of
International GL have documented a 30% risk reduction
induced by statin treatment, thus suggesting that the risk
of CV events still remains high and deﬁnes the so called
“forgotten majority”. A possible explanation for this
observation is that following the GL strategy, the treat-
ment of dyslipidemia starts to late when the vascular
damage is already established. Therefore, the availability of
a nutraceutical treatment with a documented efﬁcacy and
tolerability which allows an early reduction of plasma LDL
c levels may possibly improve not only the strategies ofpopulation prevention but also induce a further improve-
ment of the individual cardiovascular prognosis.Functional foods and cardio-metabolic diseases: the
role of dietary ﬁber7
Introduction
Cardio-metabolic diseases are one of the major causes of
mortality worldwide. Hence, huge efforts have been made
to ﬁnd easy strategies for the prevention of these diseases
and the management of disease-related risk factors.
Diet and its components, having pleiotropic effects,
represent one of the best approach to reduce cardio-
metabolic risk. In this light, dietary ﬁber (DF) has been
extensively studied and, so far, available evidence supports
the health beneﬁts of its consumption.
As a matter of fact, several prospective studies have
highlighted the inverse association between DF intake and
cardiovascular risk. A remarkable pooled analyses of ten
cohort studies (nZ 2,506,581 from USA and Europe) [153]
showed that consumption of DF was inversely associated
with risk of coronary heart disease. In particular, a 14%
reduction of the risk was observed for every 10 g/day in-
crease in DF intake, especially those from cereal and fruits.
Similar trends have been found more recently. First of all,
in the NIH-AARP cohort [154], the highest quintile DF
intake (28 g/day) was associated with a lower risk of death
from cardiovascular disease compared to the lowest
quintile (12 g/day). Moreover, the National Health and
Nutrition Examination Survey [155] showed the associa-
tion between high intake of DF and low prevalence of
cardio-metabolic risk factors (metabolic syndrome,
inﬂammation and obesity).
Hence, evidence-based guidelines recommend a daily
ﬁber intake from 25 to 30 g, preferring ﬁber-rich foods
such as fruits, vegetables, whole grains, legumes and
nuts [156e158]. However, worldwide the mean ﬁber
intake is still lower than the recommended daily dose,
even in the Mediterranean countries [155,159e161]; in this
light, functional foods, as additional sources of ﬁbers, may
contribute to health promotion in the general population.
Functional foods are by deﬁnition similar in appearance
to traditional products but have been modiﬁed to bring
beneﬁcial effects beyond nutrients supplying [162]. In
addition, in 2002 the Institute of Medicine (IOM) intro-
duced the concept of functional ﬁber as “isolated, non-
digestible carbohydrates that have beneﬁcial physiological
effects in humans” [156]; it can be added to processed
foods to improve health beneﬁts of goods. Of course,
functional foods or ﬁber need a scientiﬁcally based effect
to get a claim.
So far, evidence available from clinical trials focusing on
the effects of functional foods or ﬁbers is still insufﬁcient.
This conclusion may be due, in part, to two major factors:
a) short duration of the trials does not allow relevant
Figure 5 Possible mechanism of action of dietary ﬁber. (Source: Riv-
ellese et al. [179]). CCK: cholecystokinin; CHO: carbohydrates; FFA: free
fatty acids; GI: glycemic index; GIP: gastric inhibitory polypeptide; GLP-
1: glucagon-like peptide 1; SCFA: short chain fatty acids.
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ces of ﬁber have not the same physiologic roles.
Therefore, until now, only few types of ﬁber have ach-
ieved a “health claim” by the Food and Drugs Adminis-
tration (FDA) and the European Food Safety Agency (EFSA).
In addition, very few studies have focused on the
evaluation of mechanisms of ﬁbers as primary goal.
Thus, this viewpoint aims to 1) brieﬂy summarize the
effects of ﬁber, from ﬁber-rich foods or dietary supple-
ments, on major cardio-metabolic risk factors (overweight/
obesity, glucose tolerance, blood lipids, inﬂammation); 2)
highlight the evidence on mechanisms of action of ﬁber; 3)
identify possible strategies to increase ﬁber consumption.
Effects of dietary ﬁber on cardio-metabolic risk factors
DF consumption has been associated with a better body
weight control, even in the long term [163,164]. A land-
mark review by Wanders and colleagues [165] have sum-
marized the evidence on the effect of different type of DF
on body weight, appetite and energy intake. The main
conclusions of the review were that more viscous ﬁbers,
especially b-glucans, inﬂuence appetite and acute energy
intake, whereas no clear association between type of ﬁber
and body weight control in the long-term was observed.
Fiber-rich foods are often characterized by a lower
glycemic index (GI) compared with other foods. This
characteristic avoids acute increase of blood glucose levels
in the postprandial period, inducing beneﬁcial effects on
glucose tolerance in both diabetic and non-diabetic people
[166].
Among ﬁbers, b-glucan (4 g) from whole or processed
oat and barley seems to have the greatest effect on plasma
glucose [167]; however, there is evidence that other
sources of ﬁber may affect glycemic homeostasis. In
particular, a high intake of fruits, vegetables, legumes and
whole grain has shown to reduce signiﬁcantly post-
prandial glucose and insulin and glycemic variability [168].
Moreover, a signiﬁcant reduction of postprandial
plasma insulin levels was observed after 12-week con-
sumption of whole grain-based products [169].
In addition, the so called “second meal effect” of ﬁber,
especially from whole grains and legumes, has been
demonstrated. As a matter of fact, there is evidence that
having ﬁber-rich foods at breakfast brings down plasma
glucose levels during the rest of the day, whereas their
intake at dinner leads to lower plasma glucose levels
before breakfast the following morning [170].
Furthermore, the lowering effect on LDL-cholesterol of
DF is well documented; a meta-analyses of randomized
controlled trials clearly showed that legumes consumption
can decrease total and LDL-cholesterol (11.8 mg/dl and
8.0 mg/dl, respectively) [171].
Interestingly, this effect has been obtained also with
other ﬁber sources (whole grains, fruits and vegetables) in
healthy subjects [172] as well in diabetic patients
[168,173].
Price et al. [174] showed a signiﬁcant reduction of LDL-
cholesterol levels after the consumption of aleurone-enriched products (bread and breakfast cereal; aleurone
27 g/day) suggesting a potential role of functional foods in
the modulation of LDL-cholesterol.
The effect of ﬁber on triglycerides levels is still not
convincing even if an improvement of postprandial levels
was observed after a test meal rich in oat or wheat ﬁber.
Moreover, a signiﬁcant reduction of triglycerides in
chylomicron was detected after wheat-meal [175].
Finally, inﬂammation is a well-established risk factor
for cardiovascular disease (CVD). Overall the evidence has
shown that DF intake signiﬁcantly inﬂuences C-reactive
protein (CRP), a marker of inﬂammation [176].
Moreover, the source of ﬁber may have an important
role in inﬂuencing inﬂammation. As a matter of fact, the
consumption of whole wheat-ﬁber products had no effect
on inﬂammation markers [169], whereas de Mello et al.
[177] have shown that whole rye bread intake leads to a
signiﬁcant reduction in CRP levels.
Recently, an improvement of inﬂammation markers
was observed after the 4 weeks-supplementation of
aleurone-enriched goods (bread and breakfast cereals; al-
eurone 27 g/day) [178].
The main mechanisms behind these beneﬁts are shown
in Fig. 5. DF affects gastric emptying, inﬂuencing absorp-
tion rate of dietary carbohydrates and lipids, gut hormones
secretion and satiety feelings. Besides it reach the colon
where they are fermented by gut microbiota with the
consequent production short chain fatty acids (acetate,
propionate and butyrate) that improve glucose homeo-
stasis and lipid metabolism and inﬂuence microbiota
proﬁle [179].Functional foods enriched with dietary ﬁber
Although the health beneﬁts of DF are well established, in
western countries DF consumption does not ﬁt with rec-
ommendations, as reported before [155,159e161].
This lack of compliance may be due to several reasons.
As a matter of fact ﬁber-rich food are less appealing than
the reﬁned ones, especially for taste and ﬂavor [180]; in
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require long cooking time, or may induce intestinal
discomfort. Moreover, socio-cultural habits have changed
over the years: many people are used to have their meals
in restaurants and cafeterias where the choice of ﬁber rich
foods is often rather problematic [181]. Ready-to-eat
functional foods enriched with ﬁber can circumvent
these problems, thus improving the overall dietary habits
of western populations. Against this background, func-
tional foods resembling usual bakery products for their
taste and ﬂavor, have been additioned with ﬁbers extrac-
ted from legumes, cereals or other vegetable products.
These products have been tested for their health beneﬁts
in vivo trough clinical trials and have been shown to be
effective on glucose and lipid metabolism.
Within this context, we have shown that bakery prod-
ucts enriched with b-glucan and other bioactive com-
pounds (u3 fatty acids, folates and tocopherols) reduce
fasting plasma triglycerides, postprandial chylomicrons,
and increase satiety feeling, thus possibly preventing
overfeeding and contributing to reduce the risk of over-
weight. Besides, in our study they decreased elevated
plasma homocysteine levels which are indicated as a
marker of an increased cardiovascular risk [182].
Thence, the introduction of functional foods enriched in
DF e alone or in combination with other bioactive com-
pounds e in the habitual diet may represent an useful
strategy to improve cardio-metabolic state in high-risk
subjects but also to prevent cardio-metabolic diseases;
promoting the use of both natural foods and functional
foods might facilitate compliance to a healthy diet with a
signiﬁcantly higher ﬁber intake than it is usually
consumed in western populations.
The Mediterranean diet: an historical perspective and
where we are now8
Nutrigenomics, nutrigenetics and functional foods
The genetic revolution that we have experienced in the
past several decades has created new and exciting areas of
investigation related to the interaction between foods,
nutrients and our genetic make up to determine our sus-
ceptibility to disease and our ability to prevent or treat
common conditions (i.e. cardiovascular disease, cancer,
diabetes, obesity, cognitive decline and dementia, inﬂam-
matory bowel disease, etc. etc.) [183e185]. Environment
and foods in particular have been shown, through exper-
imental data, that they may have the ability to regulate
gene expression and genetic structure [186]. The ultimate
goals of these disciplines is to develop the ability to pro-
vide nutritional counseling to individuals based on a
detailed study of their genetic proﬁle and the speciﬁc ef-
fects that certain foods, food constituents and nutrients
may have on the structure and function of genes and their
ability to prevent or cause speciﬁc conditions [187].8 The authors of this section are Trevisan M, Misciagna G, Krogh V,
Panico S, Della Valle E, and Farinaro E.While promising and exciting, at the moment however
these new disciples are in their infancy and we have not
have yet deﬁnite scientiﬁc evidence that the effects
observed in experimental and small clinical studies have
real preventive and clinical implications.
While we wait for this evidence we have to rely on the
existing knowledge and provide counsel to individual
based on the dietary and food patterns that have been
identiﬁed and proven to have healthful and beneﬁcial ef-
fects on the life of both individuals and populations. One of
these patterns that has received substantial amount of
attention is the so called “Mediterranean diet”
Mediterranean diet
The term Mediterranean used together with diet, food or
cuisine has become a synonymous of a healthful and
tasteful pattern of eating. The press is full of articles, book,
monographs that exalt the Mediterranean diet as a way to
“enjoy food” while ensuring a long and healthy life.
This interest and fascination with the “Mediterranean
Diet” is the result of more than ﬁfty years of medical and
nutritional studies conducted by researchers around the
world. It is commonly accepted that the interest in the
food of the southern European countries that are
bordering the Mediterranean sea, started in the early
ﬁfties with the work by one of the famous nutritionists of
the twentieth century, Dr. Ancel Keys. He launched and
organized the Seven Countries Study, an epidemiological
investigation on the role of diet and other cardiovascular
risk factors in the etiology of cardiovascular disease and
death [188e190]. The study was initiated based on his
observations that in countries like Greece, Italy and Japan
the cases of myocardial infraction (ate least those in the
hospitals) were much lower than those he had observed in
Minnesota and those in Finland. Another important ﬁgure
in the design and launching of the seven countries study
was Dr. Paul Dudley White, by many considered the father
of modern cardiology.
The study, composed of sixteen cohorts in seven
countries (Finland, Greece, Italy Japan, the Netherlands,
USA and former Yugoslavia), was one of the ﬁrst examples
of a successful international collaboration in medical
research and, while with important study design limita-
tions (especially by today’s standards), represented a
formidable task for the early ﬁfties and has represented,
over the years, an important source of information on the
effect of diet on health and in cardiovascular and chronic
disease epidemiology. Moreover has represented the
training ground for generations of health scientists in
multiple disciplines.
The Seven countries study was able to show a signiﬁ-
cant and relevant association between diet and Coronary
Heart Disease (CHD) (incidence and mortality). In partic-
ular a signiﬁcant and direct relationship between % of
calories from saturated fat and CHD and a signiﬁcant and
inverse relationship between the consumption of mono-
unsaturated fats and CHD. The data from the 15 year
mortality follow-up were particularly signiﬁcant in
Functional foods 1293showing an inverse association between Coronary Deaths
and the ratio of the dietary Monounsaturated/Saturated
fats [188e190].
While olive oil has been considered the main compo-
nent of the MD, many constituents of this dietary pattern
have been identiﬁed to have potential beneﬁcial effects on
health, these include: wine, garlic, ﬁsh, vegetables, le-
gumes, almonds and other nuts [191,192].
The data of 15-year follow-up of the Seven Countries
Study have been followed by numerous scientiﬁc articles
showing relevant inverse relationships between the
Mediterranean Diet, and/or its constituents, and either
CHD or its risk factors [193e196].
More recent investigations have been able to ﬁnd pro-
tective effects of the MD or its constituents in other
chronic disease like stroke, colorectal cancer, diabetes,
dementia, wheeze and atopy in children, and all-cause
mortality. The bulk of the observations to date come from
observational studies, therefore leaving open the doubt
regarding a cause-effect relationship; however a recent
randomized population based clinical trial were able to
show a signiﬁcant effect of the MD (either olive oil or
mixed nuts) in the prevention of Cardiovascular Disease in
individual at high risk for this disease [197].
Based on these ﬁndings, nutritionist at the Harvard
School of Public health developed the Mediterranean Diet
Pyramid [198], an attempt to deﬁne the component of a
healthy diet based on the food choices of a traditional MD.
This diet is characterized by large amounts of fruit, vege-
tables, and vegetarian proteins, moderate amounts of
whole grains, small amounts of red meat, and regular use
of ﬁsh, olive oil, and nuts [199].
This pyramid was developed in contrast to the USDA
Food Guide Pyramid that emphasized low fat foods.
The scientiﬁc and public interest in the “Mediterranean
Diet” has been recently heightened by the UNESCO
through the inclusion of the Mediterranean Diet among its
list of “Intangible Cultural Heritages”.
The clinical and epidemiological investigations on the
association between MD and health have been accompa-
nied by a vast number of basic science and clinical inves-
tigation exploring the detailed mechanisms that could link
the consumption of a Mediterranean type of diet with
beneﬁcial health outcomes. This detailed studies, while
useful in helping us understand the true mechanisms
underlying the beneﬁcial effects of MD, have focused the
attention often on a minimalistic and reductionist
approach to the role of MD on health, focused on the foods
per se and the nutrients and lost track of the fact that the
MD, like all other dietary patterns, is not just the compi-
lation of the foods and nutrients ingested but is strictly
linked to social factors and norms and the forces that
shaped the dietary pattern over the centuries i.e. the ter-
ritory, the life style habits, economic conditions, climate,
etc.
In order to address this issue it may be of value to
analyze the status of the MD and the current health status
in some of the areas that have historically been charac-
terized by an MD type diet.The Mediterranean basin is the region of the world
composed of the lands around the Mediterranean Sea. The
basin covers portions of three continents, Europe, Asia and
Africa, and the lands surrounding the water share a similar
weather pattern “Mediterranean climate” with mild, rainy
winters and hot, dry summer. The vegetation is charac-
terized by forests composed generally of broadleaf trees
and coniferous and scrublands. The olive tree is very
prevalent in many areas of the Mediterranean basin and
has come to represent this region of the world.
Many of the countries surrounding the Mediterranean
Sea experience big variations in climate and geography
within their boundaries, with the lands surrounding the
sea characterized by the typical Mediterranean climate
and other portions, far from the sea, experiencing very
different weather pattern. Italy and France are good
example of these within country variations with dietary
pattern being strongly inﬂuenced by the climate i.e.
southern Italy is characterized by a typical MD pattern
while the northern part of the country is characterized
more by a continental dietary pattern, a pattern where
traditionally olive oil is substituted by butter, ﬁsh is
substituted by meat, and the consumption of vegetables is
much reduced.
Italy therefore represents an ideal place where the
variation in dietary pattern can be exploited for scientiﬁc
purposes.
The southern part of Italy was one of the regions that
Dr. Keys visited as part of his scientiﬁc travels and where
he noticed the paucity of people suffering from heart at-
tacks compared to his Minnesota. The rural diet of the
small towns of southern Italy (i.e. Nicotera) inspired him
and became one of the launching steps of the seven
countries study.
Unfortunately as we embark in analysis of the current
situation of southern Italy we ﬁnd disappointing and dis-
heartening news. The region that once was characterized
by low CHD mortality and was one of the centerpieces of
the seven countries study is experiencing now the highest
mortality for cardiovascular Disease and Diabetes in the
country [200]. These disturbing facts are made even more
frightening by the data showing that southern Italy is the
part of Italy with the highest prevalence of overweight and
obesity [201], pointing out to a future potential worsening
of the current unhealthy trends. The progressive
improvement in socio-economic conditions that has taken
place in industrialized countries in the second half of the
20th century has produced substantial life style changes.
This change has brought about the mechanization of most
working activities and transportation means, a remarkable
decrease in physical activity e and therefore, in energy
expenditure, together with an increase in food availability;
as a result eating habits are now characterized by excess
and inadequacy. The main change is represented by a
massive exposure to energy dense diets, rich in animal fat,
cholesterol, reﬁned sugars, salt and alcohol, and a low
nutrient/calorie ratio. These are the features of modern
lifestyles that have led to overweight and obesity epi-
demics and, consequently, to an increase in the incidence
9 The authors of this section are: Farinaro E, Assmann G.
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addition, the number of women and youngsters who
smoke has gone up, and this has further increased car-
diovascular disease risk.
Clearly part of the observed negative trends is the result
of a national trend in lifestyle change in particular in food
consumption that is moving away from the traditional MD,
with the ratio of calories intake/calories expended
becoming more and more unhealthy do the increased
sedentary life habits, the advent of fast foods, etc. This
phenomenon has affected both urban and rural areas of
southern Italy; however important role in this worsening
of the health proﬁle of southern Italian, especially those
living in the urban areas, is played by the living conditions
(trafﬁc, air pollution, violence etc.) that is plaguing the
urban areas and that cannot be overcome by ingestion of
few healthy foods.
Another important aspect of the deterioration of the
diet is the nature of the foods consumed that is the result
of globalization and the industrial trends in the food
industry.
One of the main reasons why the people leaving in the
lands surrounding the Mediterranean basin consumed a
healthy diet was the climatic conditions of the lands they
inhabited and the effect of these conditions on the agri-
cultural productions. Traditionally vegetable were plentiful
and available from consumption within hours from the
picking; today the vegetables and fruits may travel thou-
sands of miles, fruits are artiﬁcially ripened and months
can go by before consumption, canned and frozen foods
have become more popular.
Grains in the traditional MD were whole grain and non-
reconstituted, today they have been replaced by reﬁned
and reconstituted grains.
Cheeses and meats were used in moderation and they
were coming from animals raised through grazing and
therefore the meat was characterized by a lower content of
fats [202].
Similar negative trends of food and lifestyle habits, so-
cial circumstances and health indicators have been shown
in other areas of the Mediterranean basin [203]. We are
therefore witnesses to a paradox where, while the world is
praising and attempting to adopt the Mediterranean life-
style, the region that was characterized by the MD are
losing it with the expected signiﬁcant negative health
consequences.
What’s happening should help us understand that our
effort to improve the health of individuals and populations
shouldnot andcannot focuson individual food itemschoices
but needs to consider the food we eat in the social context.
The relevance of the social context is well described by
the UNESCO document describing the rationale for the
inclusion of the MD in its list of the world “Intangible
Cultural Heritages”.
. “The Mediterranean diet constitutes a set of skills,
knowledge, practices and traditions ranging from the
landscape to the table, including the crops, harvesting,
ﬁshing, conservation, processing, preparation and,
particularly, consumption of food. The Mediterraneandiet is characterized by a nutritional model that has
remained constant over time and space, consisting
mainly of olive oil, cereals, fresh or dried fruit and
vegetables, a moderate amount of ﬁsh, dairy and meat,
and many condiments and spices, all accompanied by
wine or infusions, always respecting beliefs of each
community. However, the Mediterranean diet (from
the Greek diaita or way of life) encompasses more than
just food. It promotes social interaction, since
communal meals are the cornerstone of social customs
and festive events. It has given rise to a considerable
body of knowledge, songs, maxims, tales and
legends. The system is rooted in respect for the terri-
tory and biodiversity, and ensures the conservation
and development of traditional activities and crafts
linked to ﬁshing and farming in the Mediterranean
communities”.......Conclusive remarks9
Mounting evidence supports the hypothesis that func-
tional foods containing physiologically-active components
may enhance health. This ﬁeld, however, is at its very
beginning, additional research is necessary to substantiate
the potential health beneﬁt of those foods for which the
diet-health relationships are not scientiﬁcally validated to
a sufﬁcient extent.
Diet exerts a strong effect on diseases known as “single-
gene autosomal recessive disorders”, examples of which
are phenylketonuria, galactosemia, and fructose intoler-
ance. These conditions can be managed by personalized
nutrition strategies.
More than 6000 human monogenic disorders have
been identiﬁed, including over 100 protein-based meta-
bolic disorders. Some are rare and complex dietary dis-
eases, namely, fatty-acid oxidation disorders, organic acid
metabolism disorders, urea cycle defects and glycogen
storage disease. Patients may reduce their intake of the
dietary substrates or metabolites that accumulate in these
conditions and nutrigenomics will improve prevention
and treatment by identifying speciﬁc mutations or haplo-
type combinations that modulate the dietary response in
affected patients. In multifactorial pathologies like car-
diovascular disease, obesity, type 2 diabetes mellitus,
cancer etc., nutrigenomic studies have shown that most of
them are amenable to dietary intervention that may
modulate their onset and progression.
In the last ten years, there has been remarkable prog-
ress in the study of geneeenvironment interaction, which
has led to a new area of knowledge: nutrigenetics and
nutrigenomics. This ﬁeld is now available to patients to
help them to improve their health.
Nutrigenetics aims at identifying the genetic suscepti-
bility to the effect of nutrients based on the architecture of
the genome of each individual.
Nutrigenomics studies the effects of food and food
constituents on gene expression.
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disease identiﬁcation and prediction as well as for disease
prevention and treatment.
Use of dietary supplements has increased markedly in
recent years, across several countries, because of the
perception that antioxidant vitamins and minerals may
reduce the risk of cardiovascular disease (CVD), cancer and
other chronic diseases. However, there is inconclusive trial
evidence for a role of dietary supplements in chronic dis-
ease prevention, at least among healthy individuals in the
general population. Nevertheless, from a public health
perspective, it is extremely important to understand the
health effects of a nutrient, such as selenium-frequently
supplemented; however, at present the widespread use of
dietary supplements such as selenium for cardio-
metabolic disease prevention in the general population is
not justiﬁed and should not be encouraged.
There is evidence from longitudinal cohort studies that
certain classes of food and dietary patterns are beneﬁcial
in primary prevention. The results of these studies have
led to the identiﬁcation of putative functional foods. The
mechanisms by which these foods exert effects are com-
plex, but are probably related to the macro- and micro-
nutrient content of the food, and to the presence of other
constituents of the diet. The beneﬁts observed may
depend on the baseline risk factors, and state of existing
diseases, may be dose dependent, and may be affected by
the preparation of the food. The beneﬁts of functional food
have seldom been reproduced by providing isolated
components of foods as supplements. It appears essential
that before health claims are made for particular foods,
in vivo randomized, double-blind, placebo-controlled tri-
als of clinical end-points are necessary to establish clinical
efﬁcacy; these studies can demonstrate efﬁcient absorp-
tion and beneﬁcial effects on the cardiovascular risk
proﬁle.
Prospective cohort studies have shown that eating ﬁsh
once a week compared to eating ﬁsh less often is associ-
ated with a signiﬁcantly lower risk of fatal CHD. Based on
these results it should be useful recommend to both in-
dividuals without and with a history of cardiovascular
disease to eat fatty ﬁsh at least once or lean ﬁsh twice a
week. The advantage of this recommendation on the use of
ﬁsh oil supplements is that ﬁsh, in particularly fatty ﬁsh, is
a rich source of the omega-3 fatty acids, as well as minerals
such as potassium and calcium, and vitamins, such as
vitamin D and vitamin B12. However, ﬁsh is not a panacea
for CHD prevention. The largest risk reduction will be
obtained if the recommended ﬁsh consumption is a
component of a nutritionally adequate diet.
Diet and its components, having pleiotropic effects,
represent one of the best approach to reduce cardio-
metabolic risk. In this light, dietary ﬁber (DF) has been
extensively studied and, so far, available evidence supports
the health beneﬁts of its consumption.
In fact, several prospective studies have highlighted the
inverse association between DF intake and cardiovascular
risk. A remarkable pooled analysis of ten cohort studies
has shown that consumption of DF was inverselyassociated with risk of coronary heart disease. Thence, the
introduction of functional foods enriched in DF e alone or
in combination with other bioactive compounds e in the
habitual diet may represent an useful strategy to improve
the cardio-metabolic state in high-risk people and thus
prevent cardio-metabolic diseases; promoting the use of
both natural and functional foods might facilitate adher-
ence to a healthy diet with a signiﬁcantly higher ﬁber
intake compared with the common nutritional habits of
western populations.
Since there is need for research work aimed at devising
personalized diet, it seems more than reasonable the latter
be modeled on Mediterranean diet, given the large body of
evidence of its healthful effects.
A wealth of recent international research studies has
provided clear evidence of the crucial role played by di-
etary habits for cardiovascular prevention. There is strong
evidence in favor of the protective role of a balanced diet,
based on fruit and vegetables and low in animal fat, in
reducing important risk factors for cardiovascular disease,
such as high cholesterol levels.
The Mediterranean diet e which captured the attention
of the scientiﬁc community involved in nutrition and
preventive cardiology e is a nutritional model whose or-
igins go back to the traditional diet adopted in European
countries bordering the Mediterranean sea, namely central
and southern Italy, Greece and Spain; this diet has become
quite widespread, especially in the last decades in coun-
tries with highly developed economies, such as the US.
These models all share a large intake of bread, fruit, ce-
reals, olive oil, and ﬁsh; the populations living in the
Mediterranean regions have a lower incidence of cardio-
vascular diseases than the North American ones, whose
diet is characterized by high intake of animal fat. A
possible explanation is that most of the fat used in Medi-
terranean cuisines derives from olive oil, which has been
proven to reduce serum cholesterol levels.References
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